Psychiatry Research: Neuroimaging, 40:269-270
Elsevier

Author Index for 1990-91

Alexandropoulos, K. 35:137
Alliger, R.J. 40:79
Alper, K.R. 35:95
Alvir, J.Ma.J. 35:1
Andreasen, N.C. 40:79, 40:157
Angrist, B. 40:11
Arató, M. 40:91
Arndt, S. 40:79, 40:157
Ashtari, M. 35:1, 40:203
Barocka, A. 40:247
Barouche, F. 40:11
Bartlett, E.J. 40:11, 40:115
Bartzokis, G. 40:239
Baxter, L.R., Jr. 40:195
Beiser, M. 40:21
Berent, S. 35:49
Betley, A.T. 35:49
Biedermann, J. 40:31
Bilder, R.M. 35:1
Blazer, D.G. 40:211
Bogerts, B. 35:1, 40:49, 40:203
Boivin, M.J. 35:49
Boyko, O.B. 40:95
Brodie, J.D. 40:11, 40:115
Brown, G.M. 40:135
Burr, G. 35:39
Camargo, E.E. 40:167
Cantor-Graae, E. 40:253
Casanova, M.F. 35:149
Chabot, R.J. 35:95
Christman, D. 35:39
Cleghorn, J.M. 40:135
Cohen, G.A. 40:79, 40:157
Colter, N. 35:137
Crocq, M.-A. 35:107
Crow, T.J. 35:137
Dauphinais, I.D. 35:137
Degreef, G. 35:1, 40:203
DeLisi, L.E. 35:137
Dewey, S.L. 35:39
Dierks, T. 40:181
Doraiswamy, P.M. 40:95, 40:211
Douglass, A. 40:1
Durst, P. 35:107
Ebert, D. 40:247
Escalona, P.R. 40:95
Feistel, H. 40:247
Figiel, G.S. 40:95
Flekköy, K. 35:27
Fowler, J.S. 35:39
Franco, S. 40:135
Franzén, G. 35:27, 40:253
Frölich, L. 40:181
Garber, H.J. 40:239
Garcia-Rill, E. 40:31
Garnett, E.S. 40:135
Gershon, E.S. 35:137
Gescuk, B. 40:1
Gillespie, H. 40:69
Giordani, B. 35:49
Grady, C.L. 40:221
Grant, C. 40:69
Griswold, V.J. 40:239
Gustafson, L. 35:27
Guze, B.H. 40:195
Harris, G.J. 40:61, 40:167
Harvey, I. 35:61
Hichwa, R.D. 35:49
Hirschowitz, J. 35:39
Hitzemann, R. 35:39
Hollister, L. 40:69
Horwitz, B. 40:221
Husain, M.M. 40:31, 40:95
Iacono, W.G. 40:21
Ihl, R. 40:181
Ingvar, D.H. 40:253
Ivanovic, M. 40:69
Jernigan, T.L. 35:115
John, E.R. 35:95
Joseph, K.C. 35:91
Kaplan, R.D. 40:135
Karlson, S. 35:27
Karson, C.N. 40:31
Kim, A.H. 35:95
Kleinman, J.E. 35:149
Koeppe, R.A. 35:49
Krishnan, K.R.R. 40:95, 40:211
Kuhl, D.E. 35:49
Laska, E.M. 40:115
Lieberman, J.A. 35:1, 40:203
Lim, K.O. 35:15, 35:71
Links, J.M. 40:167
Logan, J. 35:39
MacCrimmon, D.J. 40:91
Macher, J.-P.107
Marder, S.R. 40:239
Mathew, R.J. 40:125
Maurer, K. 40:181
Mazziotta, J.C. 40:195
McDonald, W.M. 40:95, 40:211
McGuffin, P. 35:61
McLaughlin, J.A. 40:49

Mintz, J. 40:239
Mion, C.C. 40:157
Mitra, T. 40:49
Modell, J.G. 35:49
Mokrani, M.-C. 35:107
Mrak, R.E. 40:31
Mullani, N. 40:69
Murphy, G.M., Jr. 35:15
Na, C. 40:95
Nahmias, C. 40:135
Nasrallah, H.A. 40:49
Nemeroff, C.B. 40:95
Nilsson, A. 35:27
Noga, T. 40:61
Oldendorf, W.H. 40:239
Olson, S.C. 40:49
Pearlson, G.D. 40:61, 40:167
Perisic, I. 40:181
Pfefferbaum, A. 35:15, 35:71, 35:115
Phelps, M.E. 40:195
Pietrini, P. 40:221
Prichep, L.S. 35:95
Rapoport, J.L. 40:221
Rapoport, S.I. 40:221
Rhew, E.H. 40:61
Risberg, J. 35:27, 40:253
Rodriguez, G. 35:27
Rosenbloom, M.J. 35:115
Rothley, J.M. 35:49
Rotrosen, J. 40:11
Sanfilipo, M. 40:115
Schapiro, M.B. 40:221
Schlyer, D. 35:39
Schuff, N. 35:107
Schwartz, J.M. 40:195
Schwarzkopf, S.B. 40:49
Sitaram, N. 35:91
Skinner, R.D. 40:31
Sponheim, S.R. 40:21
Stevens, J.R. 35:149
Sullivan, E.V. 35:115
Swayze, V.W. II 40:79, 40:157
Swedo, S.E. 40:221
Szechtman, B. 40:135
Szechtman, H. 40:135
Szuba, M.P. 40:195
Szymanski, S. 40:203
Tancredi, 40:69
Tinklenberg, J.R. 35:115
Toone, B.K. 35:61
Tuma, I. 35:137
Vitkun, S. 35:39
Volkow, N.D. 35:39, 40:69
Warkentin, S. 35:27, 40:253
Wiesel, F.-A. 40:101
Wik, G. 40:101
Williams, W. 35:61
Wilson, W.H. 40:125
Wolf, A.P. 35:39, 40:11, 40:115
Wolkin, A. 40:11, 40:115
Woods, B.T. 40:1
Yesavage, J.A. 35:115
Zipursky, R.B. 35:15, 35:71, 35:115
Zito, J. 40:203

Psychiatry Research: Neuroimaging, 40:271-305
Elsevier

Subject Index for 1990-91

Affective disorder
aging, late onset, 40:211
aging, magnetic resonance imaging, 40:211
aging, mania, 40:211
aging, subcortical hyperintensities, 40:211
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, glucose metabolism, 40:195
Alzheimer's disease, hippocampus, 40:195
Alzheimer's disease, positron emission tomography, 40:195
basal ganglia, limbic system, 40:95
basal ganglia, magnetic resonance imaging, 40:95
basal ganglia, putamen, 40:95
electroencephalographic topography, serotonin, 40:91
frontal lobe, Alzheimer's disease, 40:195
frontal lobe, glucose metabolism, 40:195
frontal lobe, hexamethylpropylene-amineoxime (HMPAO), 40:247
frontal lobe, hippocampus, 40:195
frontal lobe, limbic system, 40:247
frontal lobe, positron emission tomography, 40:195
frontal lobe, single photon emission computed tomography, 40:247
frontal lobe, sleep deprivation, 40:247
glucose metabolism, Alzheimer's disease, 40:195
glucose metabolism, frontal lobe, 40:195
glucose metabolism, hippocampus, 40:195
glucose metabolism, positron emission tomography, 40:195
hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
hippocampus, Alzheimer's disease, 40:195
hippocampus, frontal lobe, 40:195
hippocampus, glucose metabolism, 40:195
hippocampus, positron emission tomography, 40:195
late onset, aging, 40:211
late onset, magnetic resonance imaging, 40:211
late onset, mania, 40:211

Affective disorder continued
late onset, subcortical hyperintensities, 40:211
limbic system, basal ganglia, 40:95
limbic system, hexamethylpropylene-amineoxime (HMPAO), 40:247
limbic system, magnetic resonance imaging, 40:95
limbic system, putamen, 40:95
limbic system, single photon emission computed tomography, 40:247
limbic system, sleep deprivation, 40:247
magnetic resonance imaging, aging, 40:211
magnetic resonance imaging, basal ganglia, 40:95
magnetic resonance imaging, late onset, 40:211
magnetic resonance imaging, limbic system, 40:95
magnetic resonance imaging, mania, 40:211
magnetic resonance imaging, putamen, 40:95
magnetic resonance imaging, subcortical hyperintensities, 40:211
mania, aging, 40:211
mania, late onset, 40:211
mania, magnetic resonance imaging, 40:211
mania, subcortical hyperintensities, 40:211
positron emission tomography, Alzheimer's disease, 40:195
positron emission tomography, frontal lobe, 40:195
positron emission tomography, glucose metabolism, 40:195
positron emission tomography, hippocampus, 40:195
putamen, basal ganglia, 40:95
putamen, limbic system, 40:95
putamen, magnetic resonance imaging, 40:95
serotonin, electroencephalographic topography, 40:91
sleep, frontal lobe, 40:247
sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep, limbic system, 40:247
sleep, single photon emission computed tomography, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, hexamethylpropylene-amineoxime (HMPAO), 40:247
sleep deprivation, limbic system, 40:247
sleep deprivation, single photon emission computed tomography, 40:247

Affective disorder continued
single photon emission computed tomography, frontal lobe, 40:247
single photon emission computed tomography, hexamethylpropylene-amineoxime (HMPAO), 40:247
single photon emission computed tomography, limbic system, 40:247
single photon emission computed tomography, sleep deprivation, 40:247
subcortical hyperintensities, aging, 40:211
subcortical hyperintensities, late onset, 40:211
subcortical hyperintensities, magnetic resonance imaging, 40:211
subcortical hyperintensities, mania, 40:211
Aging
affective disorder, late onset, 40:211
affective disorder, magnetic resonance imaging, 40:211
affective disorder, mania, 40:211
affective disorder, subcortical hyperintensities, 40:211
Alzheimer's disease, cognition, 35:115
Alzheimer's disease, computed tomography, 35:115
Alzheimer's disease, Mini-Mental State Examination, 35:115
Alzheimer's disease, ventricular size, 35:115
Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
brain size, magnetic resonance imaging, 40:61
cognition, Alzheimer's disease, 35:115
cognition, computed tomography, 35:115
cognition, Mini-Mental State Examination, 35:115
cognition, ventricular size, 35:115
cognition, Wechsler Adult Intelligence Scale, 35:115
computed tomography, Alzheimer's disease, 35:115
computed tomography, cognition, 35:115
computed tomography, Mini-Mental State Examination, 35:115
computed tomography, ventricular size, 35:115
computed tomography, Wechsler Adult Intelligence Scale, 35:115
hippocampus, magnetic resonance imaging, 35:15
hippocampus, ventricular size, 35:15
late onset, affective disorder, 40:211
late onset, magnetic resonance imaging, 40:211
Aging continued
late onset, mania, 40:211
late onset, subcortical hyperintensities, 40:211
limbic system, magnetic resonance imaging, 35:15
limbic system, ventricular size, 35:15
magnetic resonance imaging, affective disorder, 40:211
magnetic resonance imaging, brain size, 40:61
magnetic resonance imaging, hippocampus, 35:15
magnetic resonance imaging, late onset, 40:211
magnetic resonance imaging, limbic system, 35:15
magnetic resonance imaging, mania, 40:211
magnetic resonance imaging, subcortical hyperintensities, 40:211
magnetic resonance imaging, ventricular size, 35:15
mania, affective disorder, 40:211
mania, late onset, 40:211
mania, magnetic resonance imaging, 40:211
mania, subcortical hyperintensities, 40:211
Mini-Mental State Examination, Alzheimer's disease, 35:115
Mini-Mental State Examination, cognition, 35:115
Mini-Mental State Examination, computed tomography, 35:115
Mini-Mental State Examination, ventricular size, 35:115
subcortical hyperintensities, affective disorder, 40:211
subcortical hyperintensities, late onset, 40:211
subcortical hyperintensities, magnetic resonance imaging, 40:211
subcortical hyperintensities, mania, 40:211
ventricular size, Alzheimer's disease, 35:115
ventricular size, cognition, 35:115
ventricular size, computed tomography, 35:115
ventricular size, hippocampus, 35:15
ventricular size, limbic system, 35:15
ventricular size, magnetic resonance imaging, 35:15
ventricular size, Mini-Mental State Examination, 35:115
ventricular size, Wechsler Adult Intelligence Scale, 35:115
Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115

Aging continued
Wechsler Adult Intelligence Scale, cognition, 35:115
Wechsler Adult Intelligence Scale, computed tomography, 35:115
Wechsler Adult Intelligence Scale, ventricular size, 35:115
Alcohol. See Ethanol
Alcoholism
computed tomography, measurement reliability, 40:1
measurement reliability, computed tomography, 40:1
ventricle-brain ratio, computed tomography, 40:1
Alzheimer's disease
affective disorder, frontal lobe, 40:195
affective disorder, glucose metabolism, 40:195
affective disorder, hippocampus, 40:195
affective disorder, positron emission tomography, 40:195
aging, cognition, 35:115
aging, computed tomography, 35:115
aging, Mini-Mental State Examination, 35:115
aging, ventricular size, 35:115
aging, Wechsler Adult Intelligence Scale, 35:115
astrocytosis, dentate gyrus, 35:149
astrocytosis, entorhinal cortex, 35:149
astrocytosis, hippocampus, 35:149
astrocytosis, post-mortem examination, 35:149
astrocytosis, schizophrenia, 35:149
blood flow, cortical circumferential analysis, 40:167
blood flow, iodoamphetamine, 40:167
blood flow, single photon emission computed tomography, 40:167
brain size, magnetic resonance imaging, 40:61
cognition, aging, 35:115
cognition, computed tomography, 35:115
cognition, Mini-Mental State Examination, 35:115
cognition, ventricular size, 35:115
cognition, Wechsler Adult Intelligence Scale, 35:115
computed tomography, aging, 35:115
computed tomography, cognition, 35:115
computed tomography, Mini-Mental State Examination, 35:115
computed tomography, neuropsychology, 35:115
Alzheimer's disease continued
computed tomography, ventricular size, 35:115
computed tomography, Wechsler Adult Intelligence Scale, 35:115
cortical circumferential analysis, blood flow, 40:167
cortical circumferential analysis, iodoamphetamine, 40:167
cortical circumferential analysis, single photon emission computed tomography, 40:167
dentate gyrus, astrocytosis, 35:149
dentate gyrus, entorhinal cortex, 35:149
dentate gyrus, hippocampus, 35:149
dentate gyrus, post-mortem examination, 35:149
dentate gyrus, schizophrenia, 35:149
electroencephalographic topography, neuropsychology, 40:181
electroencephalographic topography, severity of dementia, 40:181
entorhinal cortex, astrocytosis, 35:149
entorhinal cortex, dentate gyrus, 35:149
entorhinal cortex, hippocampus, 35:149
entorhinal cortex, post-mortem examination, 35:149
entorhinal cortex, schizophrenia, 35:149
frontal lobe, affective disorder, 40:195
frontal lobe, glucose metabolism, 40:195
frontal lobe, hippocampus, 40:195
frontal lobe, positron emission tomography, 40:195
glucose metabolism, affective disorder, 40:195
glucose metabolism, frontal lobe, 40:195
glucose metabolism, hippocampus, 40:195
glucose metabolism, positron emission tomography, 40:195
hippocampus, affective disorder, 40:195
hippocampus, astrocytosis, 35:149
hippocampus, dentate gyrus, 35:149
hippocampus, entorhinal cortex, 35:149
hippocampus, frontal lobe, 40:195
hippocampus, glucose metabolism, 40:195
hippocampus, positron emission tomography, 40:195
hippocampus, post-mortem examination, 35:149
hippocampus, schizophrenia, 35:149
iodoamphetamine, blood flow, 40:167
iodoamphetamine, cortical circumferential analysis, 40:167
iodoamphetamine, single photon emission computed tomography, 40:167

Alzheimer's disease continued
magnetic resonance imaging, brain size, 40:61
Mini-Mental State Examination, aging, 35:115
Mini-Mental State Examination, cognition, 35:115
Mini-Mental State Examination, computed tomography, 35:115
Mini-Mental State Examination, ventricular size, 35:115
Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
neuropsychology, computed tomography, 35:115
neuropsychology, electroencephalographic topography, 40:181
neuropsychology, severity of dementia, 40:181
positron emission tomography, affective disorder, 40:195
positron emission tomography, frontal lobe, 40:195
positron emission tomography, glucose metabolism, 40:195
positron emission tomography, hippocampus, 40:195
post-mortem examination, astrocytosis, 35:149
post-mortem examination, dentate gyrus, 35:149
post-mortem examination, entorhinal cortex, 35:149
post-mortem examination, hippocampus, 35:149
post-mortem examination, schizophrenia, 35:149
schizophrenia, astrocytosis, 35:149
schizophrenia, dentate gyrus, 35:149
schizophrenia, entorhinal cortex, 35:149
schizophrenia, hippocampus, 35:149
schizophrenia, post-mortem examination, 35:149
severity of dementia, electroencephalographic topography, 40:181
severity of dementia, neuropsychology, 40:181
single photon emission computed tomography, blood flow, 40:167
single photon emission computed tomography, cortical circumferential analysis, 40:167
single photon emission computed tomography, iodoamphetamine, 40:167
Alzheimer's disease continued
ventricular size, aging, 35:115
ventricular size, cognition, 35:115
ventricular size, computed tomography, 35:115
ventricular size, Mini-Mental State Examination, 35:115
ventricular size, Wechsler Adult Intelligence Scale, 35:115
Wechsler Adult Intelligence Scale, aging, 35:115
Wechsler Adult Intelligence Scale, cognition, 35:115
Wechsler Adult Intelligence Scale, computed tomography, 35:115
Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115
Wechsler Adult Intelligence Scale, ventricular size, 35:115
Amygdala
genetics, hippocampus, 35:137
genetics, magnetic resonance imaging, 35:137
genetics, schizophrenia, 35:137
genetics, temporal lobe, 35:137
genetics, ventricular size, 35:137
hippocampus, genetics, 35:137
hippocampus, magnetic resonance imaging, 35:1, 35:137
hippocampus, schizophrenia, 35:1, 35:137
hippocampus, temporal horn volume, 35:1
hippocampus, temporal lobe, 35:1, 35:137
hippocampus, ventricular size, 35:137
magnetic resonance imaging, genetics, 35:137
magnetic resonance imaging, hippocampus, 35:1, 35:137
magnetic resonance imaging, schizophrenia, 35:1, 35:137
magnetic resonance imaging, temporal horn volume, 35:1
magnetic resonance imaging, temporal lobe, 35:1, 35:137
magnetic resonance imaging, ventricular size, 35:137
schizophrenia, genetics, 35:137
schizophrenia, hippocampus, 35:1, 35:137
schizophrenia, magnetic resonance imaging, 35:1, 35:137
schizophrenia, temporal horn volume, 35:1
schizophrenia, temporal lobe, 35:1, 35:137
schizophrenia, ventricular size, 35:137
temporal horn volume, hippocampus, 35:1
temporal horn volume, magnetic resonance imaging, 35:1

Amygdala continued
temporal horn volume, schizophrenia, 35:1
temporal lobe, genetics, 35:137
temporal lobe, hippocampus, 35:1, 35:137
temporal lobe, magnetic resonance imaging, 35:1, 35:137
temporal lobe, schizophrenia, 35:1, 35:137
temporal lobe, ventricular size, 35:137
ventricular size, genetics, 35:137
ventricular size, hippocampus, 35:137
ventricular size, magnetic resonance imaging, 35:137
ventricular size, schizophrenia, 35:137
ventricular size, temporal lobe, 35:137
Anxiety
blood flow, diazepam, 40:125
blood flow, generalized anxiety disorder, 40:125
blood flow, ondansetron, 40:125
diazepam, blood flow, 40:125
diazepam, generalized anxiety disorder, 40:125
diazepam, ondansetron, 40:125
frontal lobe, glucose metabolism, 35:49 40:101
frontal lobe, homovanillic acid, 40:101
frontal lobe, laterality, 35:49
frontal lobe, positron emission tomography, 35:49, 40:101
frontal lobe, prolactin, 40:101
frontal lobe, schizophrenia, 40:101
frontal lobe, State-Trait Anxiety Inventory, 35:49
generalized anxiety disorder, blood flow, 40:125
generalized anxiety disorder, diazepam, 40:125
generalized anxiety disorder, ondansetron, 40:125
glucose metabolism, frontal lobe, 35:49, 40:101
glucose metabolism, homovanillic acid, 40:101
glucose metabolism, laterality, 35:49
glucose metabolism, positron emission tomography, 35:49, 40:101
glucose metabolism, prolactin, 40:101
glucose metabolism, schizophrenia, 40:101
glucose metabolism, State-Trait Anxiety Inventory, 35:49
homovanillic acid, frontal lobe, 40:101
homovanillic acid, glucose metabolism, 40:101
homovanillic acid, positron emission tomography, 40:101
Anxiety continued
homovanillic acid, prolactin, 40:101
homovanillic acid, schizophrenia, 40:101
laterality, frontal lobe, 35:49
laterality, glucose metabolism, 35:49
laterality, positron emission tomography, 35:49
laterality, State-Trait Anxiety Inventory, 35:49
ondansetron, blood flow, 40:125
ondansetron, diazepam, 40:125
ondansetron, generalized anxiety disorder, 40:125
positron emission tomography, frontal lobe, 35:49, 40:101
positron emission tomography, glucose metabolism, 35:49, 40:101
positron emission tomography, homovanillic acid, 40:101
positron emission tomography, laterality, 35:49
positron emission tomography, prolactin, 40:101
positron emission tomography, schizophrenia, 40:101
positron emission tomography, State-Trait Anxiety Inventory, 35:49
prolactin, frontal lobe, 40:101
prolactin, glucose metabolism, 40:101
prolactin, homovanillic acid, 40:101
prolactin, positron emission tomography, 40:101
prolactin, schizophrenia, 40:101
schizophrenia, frontal lobe, 40:101
schizophrenia, glucose metabolism, 40:101
schizophrenia, homovanillic acid, 40:101
schizophrenia, positron emission tomography, 40:101
schizophrenia, prolactin, 40:101
State-Trait Anxiety Inventory, frontal lobe, 35:49
State-Trait Anxiety Inventory, glucose metabolism, 35:49
State-Trait Anxiety Inventory, laterality, 35:49
State-Trait Anxiety Inventory, positron emission tomography, 35:49
Apomorphine
frontal lobe, glucose metabolism, 40:135
frontal lobe, never-medicated patients, 40:135
frontal lobe, positron emission tomography, 40:135
frontal lobe, schizophrenia, 40:135

Apomorphine continued
frontal lobe, temporal lobe, 40:135
glucose metabolism, frontal lobe, 40:135
glucose metabolism, never-medicated patients, 40:135
glucose metabolism, positron emission tomography, 40:135
glucose metabolism, schizophrenia, 40:135
glucose metabolism, temporal lobe, 40:135
never-medicated patients, frontal lobe, 40:135
never-medicated patients, glucose metabolism, 40:135
never-medicated patients, positron emission tomography, 40:135
never-medicated patients, schizophrenia, 40:135
never-medicated patients, temporal lobe, 40:135
positron emission tomography, frontal lobe, 40:135
positron emission tomography, glucose metabolism, 40:135
positron emission tomography, never-medicated patients, 40:135
positron emission tomography, schizophrenia, 40:135
positron emission tomography, temporal lobe, 40:135
schizophrenia, frontal lobe, 40:135
schizophrenia, glucose metabolism, 40:135
schizophrenia, never-medicated patients, 40:135
schizophrenia, positron emission tomography, 40:135
schizophrenia, temporal lobe, 40:135
temporal lobe, frontal lobe, 40:135
temporal lobe, glucose metabolism, 40:135
temporal lobe, never-medicated patients, 40:135
temporal lobe, positron emission tomography, 40:135
temporal lobe, schizophrenia, 40:135

Arecoline
electroencephalographic topography, polysomnography, 35:91
electroencephalographic topography, sleep, 35:91
polysomnography, electroencephalographic topography, 35:91
sleep, electroencephalographic topography, 35:91

Basal ganglia
affective disorder, limbic system, 40:95

Basal ganglia continued
affective disorder, magnetic resonance imaging, 40:95
affective disorder, putamen, 40:95
frontal lobe, glucose, 40:115
frontal lobe, neuroleptics, 40:115
frontal lobe, positron emission tomography, 40:115
frontal lobe, schizophrenia, 40:115
glucose, frontal lobe, 40:115
glucose, neuroleptics, 40:115
glucose, positron emission tomography, 40:115
glucose, schizophrenia, 40:115
limbic system, affective disorder, 40:95
limbic system, magnetic resonance imaging, 40:95
limbic system, putamen, 40:95
magnetic resonance imaging, affective disorder, 40:95
magnetic resonance imaging, limbic system, 40:95
magnetic resonance imaging, putamen, 40:95
magnetic resonance imaging, schizophrenia, 40:157
magnetic resonance imaging, tardive dyskinesia, 40:157
neuroleptics, frontal lobe, 40:115
neuroleptics, glucose, 40:115
neuroleptics, positron emission tomography, 40:115
neuroleptics, schizophrenia, 40:115
positron emission tomography, frontal lobe, 40:115
positron emission tomography, glucose, 40:115
positron emission tomography, neuroleptics, 40:115
positron emission tomography, schizophrenia, 40:115
putamen, affective disorder, 40:95
putamen, limbic system, 40:95
putamen, magnetic resonance imaging, 40:95
schizophrenia, frontal lobe, 40:115
schizophrenia, glucose, 40:115
schizophrenia, magnetic resonance imaging, 40:157
schizophrenia, neuroleptics, 40:115
schizophrenia, positron emission tomography, 40:115
schizophrenia, tardive dyskinesia, 40:157
tardive dyskinesia, magnetic resonance imaging, 40:157
tardive dyskinesia, schizophrenia, 40:157

Benzodiazepine. See Diazepam
Blood flow
Alzheimer's disease, cortical circumferential analysis, 40:167
Alzheimer's disease, iodoamphetamine, 40:167
Alzheimer's disease, single photon emission computed tomography, 40:167
anxiety, diazepam, 40:125
anxiety, ondansetron, 40:125
Chicago Word Fluency Test, neuropsychology, 40:253
cortical circumferential analysis, Alzheimer's disease, 40:167
cortical circumferential analysis, iodoamphetamine, 40:167
cortical circumferential analysis, single photon emission computed tomography, 40:167
diazepam, anxiety, 40:125
diazepam, generalized anxiety disorder, 40:125
diazepam, ondansetron, 40:125
frontal lobe, long-term followup, 40:253
frontal lobe, schizophrenia, 35:27, 40:253
frontal lobe, symptom severity, 35:27
generalized anxiety disorder, diazepam, 40:125
generalized anxiety disorder, ondansetron, 40:125
iodoamphetamine, Alzheimer's disease, 40:167
iodoamphetamine, cortical circumferential analysis, 40:167
iodoamphetamine, single photon emission computed tomography, 40:167
long-term followup, frontal lobe, 40:253
long-term followup, schizophrenia, 40:253
neuropsychology, Chicago Word Fluency Test, 40:253
neuropsychology, schizophrenia, 40:253
neuropsychology, Wisconsin Card Sort Test, 40:253
ondansetron, anxiety, 40:125
ondansetron, diazepam, 40:125
ondansetron, generalized anxiety disorder, 40:125
schizophrenia, frontal lobe, 35:27, 40:253
schizophrenia, long-term followup, 40:253
schizophrenia, neuropsychology, 40:253
schizophrenia, symptom severity, 35:27
schizophrenia, Wisconsin Card Sort Test, 40:253
single photon emission computed tomography, Alzheimer's disease, 40:167
single photon emission computed tomography, cortical circumferential analysis, 40:167
Blood flow continued
single photon emission computed tomography, iodoamphetamine, 40:167
symptom severity, frontal lobe, 35:27
symptom severity, schizophrenia, 35:27
Wisconsin Card Sort Test, neuropsychology, 40:253
Wisconsin Card Sort Test, schizophrenia, 40:253
Brain electrical activity mapping. See electroencephalographic topography
Brain stem
locus ceruleus, neuropathology, 40:31
locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
locus ceruleus, pedunculopontine nucleus, 40:31
locus ceruleus, schizophrenia, 40:31
neuropathology, locus ceruleus, 40:31
neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
neuropathology, pedunculopontine nucleus, 40:31
neuropathology, schizophrenia, 40:31
nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
pedunculopontine nucleus, locus ceruleus, 40:31
pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
pedunculopontine nucleus, neuropathology, 40:31
pedunculopontine nucleus, schizophrenia, 40:31
schizophrenia, locus ceruleus, 40:31
schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
schizophrenia, neuropathology, 40:31
schizophrenia, pedunculopontine nucleus, 40:31
Brain volume
computer methods, magnetic resonance imaging, 40:61
magnetic resonance imaging, computer methods, 40:61
Cerebral blood flow. See Blood flow
Clomipramine
electroencephalographic topography, evoked potentials, 40:91
electroencephalographic topography, fluoxetine, 40:91

Clomipramine continued
electroencephalographic topography, laterality, 40:91
electroencephalographic topography, P300, 40:91
electroencephalographic topography, serotonin, 40:91
evoked potentials, electroencephalographic topography, 40:91
evoked potentials, fluoxetine, 40:91
evoked potentials, laterality, 40:91
evoked potentials, P300, 40:91
evoked potentials, serotonin, 40:91
fluoxetine, electroencephalographic topography, 40:91
fluoxetine, evoked potentials, 40:91
fluoxetine, laterality, 40:91
fluoxetine, P300, 40:91
fluoxetine, serotonin, 40:91
laterality, electroencephalographic topography, 40:91
laterality, evoked potentials, 40:91
laterality, fluoxetine, 40:91
laterality, P300, 40:91
laterality, serotonin, 40:91
P300, electroencephalographic topography, 40:91
P300, evoked potentials, 40:91
P300, fluoxetine, 40:91
P300, laterality, 40:91
P300, serotonin, 40:91
serotonin, electroencephalographic topography, 40:91
serotonin, evoked potentials, 40:91
serotonin, fluoxetine, 40:91
serotonin, laterality, 40:91
serotonin, P300, 40:91
Cocaine
alpha power, Beck Depression Scale, 35:95
alpha power, electroencephalographic topography, 35:95
alpha power, substance abuse, 35:95
Beck Depression Scale, alpha power, 35:95
Beck Depression Scale, electroencephalographic topography, 35:95
Beck Depression Scale, substance abuse, 35:95
electroencephalographic topography, alpha power, 35:95
electroencephalographic topography, Beck Depression Scale, 35:95
electroencephalographic topography, substance abuse, 35:95
Cocaine continued
substance abuse, alpha power, 35:95
substance abuse, Beck Depression Scale, 35:95
substance abuse, electroencephalographic topography, 35:95
Cognition
Alzheimer's disease, Brief Cognitive Rating Scale, 40:181
Alzheimer's disease, electroencephalographic topography, 40:181
Brief Cognitive Rating Scale, Alzheimer's disease, 40:181
Brief Cognitive Rating Scale, electroencephalographic topography, 40:181
electroencephalographic topography, Alzheimer's disease, 40:181
electroencephalographic topography, Brief Cognitive Rating Scale, 40:181
Computed tomography
admixture analysis, genetics, 35:61
admixture analysis, schizophrenia, 35:61
admixture analysis, ventricle-brain ratio, 35:61
aging, Alzheimer's disease, 35:115
aging, cognition, 35:115
aging, Mini-Mental State Examination, 35:115
aging, ventricular size, 35:115
aging, Wechsler Adult Intelligence Scale, 35:115
alcoholism, measurement reliability, 40:1
alcoholism, ventricle-brain ratio, 40:1
Alzheimer's disease, aging, 35:115
Alzheimer's disease, cognition, 35:115
Alzheimer's disease, Mini-Mental State Examination, 35:115
Alzheimer's disease, neuropsychology, 35:115
Alzheimer's disease, ventricular size, 35:115
Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
cerebral asymmetry, laterality, 35:71
cerebral asymmetry, measurement methods, 35:71
cognition, aging, 35:115
cognition, Alzheimer's disease, 35:115
cognition, Mini-Mental State Examination, 35:115
cognition, ventricular size, 35:115
cognition, Wechsler Adult Intelligence Scale, 35:115
genetics, admixture analysis, 35:61

Computed tomography continued
genetics, schizophrenia, 35:61
genetics, ventricle-brain ratio, 35:61
laterality, cerebral asymmetry, 35:71
laterality, measurement methods, 35:71
measurement methods, cerebral asymmetry, 35:71
measurement methods, laterality, 35:71
measurement reliability, alcoholism, 40:1
measurement reliability, ventricle-brain ratio, 40:1
Mini-Mental State Examination, aging, 35:115
Mini-Mental State Examination, Alzheimer's disease, 35:115
Mini-Mental State Examination, cognition, 35:115
Mini-Mental State Examination, ventricular size, 35:115
Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
neuropsychology, Alzheimer's disease, 35:115
occipital horn size, reliability, 40:21
reliability, occipital horn size, 40:21
schizophrenia, admixture analysis, 35:61
schizophrenia, genetics, 35:61
schizophrenia, stability after psychosis onset, 40:21
schizophrenia, ventricle-brain ratio, 35:61
schizophrenia, ventricular size, 40:21
stability after psychosis onset, schizophrenia, 40:21
stability after psychosis onset, ventricular size, 40:21
ventricle-brain ratio, admixture analysis, 35:61
ventricle-brain ratio, alcoholism, 40:1
ventricle-brain ratio, genetics, 35:61
ventricle-brain ratio, measurement reliability, 40:1
ventricle-brain ratio, schizophrenia, 35:61
ventricular size, aging, 35:115
ventricular size, Alzheimer's disease, 35:115
ventricular size, cognition, 35:115
ventricular size, Mini-Mental State Examination, 35:115
ventricular size, schizophrenia, 40:21
ventricular size, stability after psychosis onset, 40:21
ventricular size, Wechsler Adult Intelligence Scale, 35:115
Wechsler Adult Intelligence Scale, aging, 35:115

Computed tomography continued
Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115
Wechsler Adult Intelligence Scale, cognition, 35:115
Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115
Wechsler Adult Intelligence Scale, ventricular size, 35:115
Crack. See Cocaine
Depression. See Affective disorder
Diazepam
anxiety, blood flow, 40:125
anxiety, generalized anxiety disorder, 40:125
anxiety, ondansetron, 40:125
blood flow, anxiety, 40:125
blood flow, generalized anxiety disorder, 40:125
blood flow, ondansetron, 40:125
generalized anxiety disorder, anxiety, 40:125
generalized anxiety disorder, blood flow, 40:125
generalized anxiety disorder, ondansetron, 40:125
ondansetron, anxiety, 40:125
ondansetron, blood flow, 40:125
ondansetron, generalized anxiety disorder, 40:125
Dorsolateral prefrontal cortex. See Frontal lobe
Electroencephalographic topography
affective disorder, serotonin, 40:91
alpha power, Beck Depression Scale, 35:95
alpha power, cocaine, 35:95
alpha power, substance abuse, 35:95
Alzheimer's disease, Brief Cognitive Rating Scale, 40:181
Alzheimer's disease, cognition, 40:181
Alzheimer's disease, neuropsychology, 40:181
Alzheimer's disease, severity of dementia, 40:181
arecoline, polysomnography, 35:91
arecoline, sleep, 35:91
Beck Depression Scale, alpha power, 35:95
Beck Depression Scale, cocaine, 35:95
Beck Depression Scale, substance abuse, 35:95
Brief Cognitive Rating Scale, Alzheimer's disease, 40:181
Brief Cognitive Rating Scale, cognition, 40:181
clomipramine, evoked potentials, 40:91
clomipramine, fluoxetine, 40:91

Electroencephalographic topography continued
clomipramine, laterality, 40:91
clomipramine, P300, 40:91
clomipramine, serotonin, 40:91
cocaine, alpha power, 35:95
cocaine, Beck Depression Scale, 35:95
cocaine, substance abuse, 35:95
cognition, Alzheimer's disease, 40:181
cognition, Brief Cognitive Rating Scale, 40:181
evoked potentials, clomipramine, 40:91
evoked potentials, fluoxetine, 40:91
evoked potentials, laterality, 40:91
evoked potentials, P300, 40:91
evoked potentials, serotonin, 40:91
fluoxetine, clomipramine, 40:91
fluoxetine, evoked potentials, 40:91
fluoxetine, laterality, 40:91
fluoxetine, P300, 40:91
fluoxetine, serotonin, 40:91
laterality, clomipramine, 40:91
laterality, evoked potentials, 40:91
laterality, fluoxetine, 40:91
laterality, P300, 40:91
laterality, serotonin, 40:91
neuropsychology, Alzheimer's disease, 40:181
neuropsychology, severity of dementia, 40:181
P300, clomipramine, 40:91
P300, evoked potentials, 40:91
P300, fluoxetine, 40:91
P300, laterality, 40:91
P300, serotonin, 40:91
polysomnography, arecoline, 35:91
serotonin, affective disorder, 40:91
serotonin, clomipramine, 40:91
serotonin, evoked potentials, 40:91
serotonin, fluoxetine, 40:91
serotonin, laterality, 40:91
serotonin, P300, 40:91
severity of dementia, Alzheimer's disease, 40:181
severity of dementia, neuropsychology, 40:181
sleep, arecoline, 35:91
substance abuse, alpha power, 35:95
substance abuse, Beck Depression Scale, 35:95
substance abuse, cocaine, 35:95
Ethanol
glucose metabolism, positron emission tomography, 35:39
Ethanol continued
positron emission tomography, glucose metabolism, 35:39
Evoked potential
clomipramine, electroencephalographic topography, 40:91
clomipramine, fluoxetine, 40:91
clomipramine, laterality, 40:91
clomipramine, P300, 40:91
clomipramine, serotonin, 40:91
electroencephalographic topography, clomipramine, 40:91
electroencephalographic topography, fluoxetine, 40:91
electroencephalographic topography, laterality, 40:91
electroencephalographic topography, P300, 40:91
electroencephalographic topography, serotonin, 40:91
fluoxetine, clomipramine, 40:91
fluoxetine, electroencephalographic topography, 40:91
fluoxetine, laterality, 40:91
fluoxetine, P300, 40:91
fluoxetine, serotonin, 40:91
laterality, clomipramine, 40:91
laterality, electroencephalographic topography, 40:91
laterality, fluoxetine, 40:91
laterality, P300, 40:91
laterality, serotonin, 40:91
P300, clomipramine, 40:91
P300, electroencephalographic topography, 40:91
P300, fluoxetine, 40:91
P300, laterality, 40:91
P300, serotonin, 40:91
serotonin, clomipramine, 40:91
serotonin, electroencephalographic topography, 40:91
serotonin, fluoxetine, 40:91
serotonin, laterality, 40:91
serotonin, P300, 40:91
Fluoxetine
clomipramine, electroencephalographic topography, 40:91
clomipramine, evoked potentials, 40:91
clomipramine, laterality, 40:91
clomipramine, P300, 40:91
clomipramine, serotonin, 40:91
electroencephalographic topography, clomipramine, 40:91
electroencephalographic topography, evoked

Fluoxetine continued
potentials, 40:91
electroencephalographic topography, laterality, 40:91
electroencephalographic topography, P300, 40:91
electroencephalographic topography, serotonin, 40:91
evoked potentials, clomipramine, 40:91
evoked potentials, electroencephalographic topography, 40:91
evoked potentials, laterality, 40:91
evoked potentials, P300, 40:91
evoked potentials, serotonin, 40:91
laterality, clomipramine, 40:91
laterality, electroencephalographic topography, 40:91
laterality, evoked potentials, 40:91
laterality, P300, 40:91
laterality, serotonin, 40:91
P300, clomipramine, 40:91
P300, electroencephalographic topography, 40:91
P300, evoked potentials, 40:91
P300, laterality, 40:91
P300, serotonin, 40:91
serotonin, clomipramine, 40:91
serotonin, electroencephalographic topography, 40:91
serotonin, evoked potentials, 40:91
serotonin, laterality, 40:91
serotonin, P300, 40:91
Fluphenazine
magnetic resonance spectroscopy, pharmacokinetics, 35:107
magnetic resonance spectroscopy, schizophrenia, 35:107
pharmacokinetics, magnetic resonance spectroscopy, 35:107
pharmacokinetics, schizophrenia, 35:107
schizophrenia, magnetic resonance spectroscopy, 35:107
schizophrenia, pharmacokinetics, 35:107
Frontal lobe
affective disorder, Alzheimer's disease, 40:195
affective disorder, glucose metabolism, 40:195
affective disorder, hexamethylpropylene-amineoxime (HMPAO), 40:247
affective disorder, hippocampus, 40:195
affective disorder, limbic system, 40:247
affective disorder, positron emission tomography, 40:195
Frontal lobe continued
affective disorder, sleep, 40:247
affective disorder, sleep deprivation, 40:247
affective disorder, single photon emission computed tomography, 40:247
Alzheimer's disease, affective disorder, 40:195
Alzheimer's disease, glucose metabolism, 40:195
Alzheimer's disease, hippocampus, 40:195
Alzheimer's disease, positron emission tomography, 40:195
anxiety, glucose metabolism, 35:49, 40:101
anxiety, homovanillic acid, 40:101
anxiety, laterality, 35:49
anxiety, positron emission tomography, 35:49, 40:101
anxiety, prolactin, 40:101
anxiety, schizophrenia, 40:101
anxiety, State-Trait Anxiety Inventory, 35:49
apomorphine, glucose metabolism, 40:135
apomorphine, never-medicated patients, 40:135
apomorphine, positron emission tomography, 40:135
apomorphine, schizophrenia, 40:135
apomorphine, temporal lobe, 40:135
basal ganglia, glucose, 40:115
basal ganglia, neuroleptics, 40:115
basal ganglia, positron emission tomography, 40:115
basal ganglia, schizophrenia, 40:115
blood flow, long-term followup, 40:253
blood flow, schizophrenia, 35:27, 40:253
blood flow, symptom severity, 35:27
correlation analysis, glucose metabolism, 40:221
correlation analysis, limbic system, 40:221
correlation analysis, obsessive-compulsive disorder, 40:221
correlation analysis, positron emission tomography, 40:221
glucose, basal ganglia, 40:115
glucose metabolism, affective disorder, 40:195
glucose metabolism, Alzheimer's disease, 40:195
glucose metabolism, anxiety, 35:49, 40:101
glucose metabolism, apomorphine, 40:135
glucose metabolism, correlation analysis, 40:221
glucose metabolism, hippocampus, 40:195
glucose metabolism, homovanillic acid, 40:101

Frontal lobe continued
glucose metabolism, laterality, 35:49
glucose metabolism, limbic system, 40:221
glucose metabolism, neuroleptics, 40:115
glucose metabolism, never-medicated patients, 40:135
glucose metabolism, obsessive-compulsive disorder, 40:221
glucose metabolism, positron emission tomography, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
glucose metabolism, prolactin, 40:101
glucose metabolism, schizophrenia, 40:101, 40:115, 40:135
glucose metabolism, State-Trait Anxiety Inventory, 35:49
glucose metabolism, temporal lobe, 40:135
hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
hippocampus, affective disorder, 40:195
hippocampus, Alzheimer's disease, 40:195
hippocampus, glucose metabolism, 40:195
hippocampus, positron emission tomography, 40:195
homovanillic acid, anxiety, 40:101
homovanillic acid, glucose metabolism, 40:101
homovanillic acid, positron emission tomography, 40:101
homovanillic acid, prolactin, 40:101
homovanillic acid, schizophrenia, 40:101
laterality, anxiety, 35:49
laterality, glucose metabolism, 35:49
laterality, positron emission tomography, 35:49
laterality, State-Trait Anxiety Inventory, 35:49
limbic system, affective disorder, 40:247
limbic system, correlation analysis, 40:221
limbic system, glucose metabolism, 40:221
limbic system, hexamethylpropyleneamine-oxime (HMPAO), 40:247
limbic system, obsessive-compulsive disorder, 40:247
limbic system, positron emission tomography, 40:247

Frontal lobe continued
limbic system, single photon emission computed tomography, 40:247
limbic system, sleep, 40:247
limbic system, sleep deprivation, 40:247
long-term followup, blood flow, 40:253
long-term followup, schizophrenia, 40:253
neuroleptics, basal ganglia, 40:115
neuroleptics, glucose, 40:115
neuroleptics, positron emission tomography, 40:115
neuroleptics, schizophrenia, 40:115
never-medicated patients, apomorphine, 40:135
never-medicated patients, glucose metabolism, 40:135
never-medicated patients, positron emission tomography, 40:135
never-medicated patients, schizophrenia, 40:135
never-medicated patients, temporal lobe, 40:135
obsessive-compulsive disorder, correlation analysis, 40:221
obsessive-compulsive disorder, glucose metabolism, 40:221
obsessive-compulsive disorder, limbic system, 40:221
obsessive-compulsive disorder, positron emission tomography, 40:221
positron emission tomography, affective disorder, 40:195
positron emission tomography, Alzheimer's disease, 40:195
positron emission tomography, anxiety, 35:49, 40:101
positron emission tomography, apomorphine, 40:135
positron emission tomography, basal ganglia, 40:115
positron emission tomography, correlation analysis, 40:221
positron emission tomography, glucose metabolism, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
positron emission tomography, hippocampus, 40:195
positron emission tomography, homovanillic acid, 40:101
positron emission tomography, laterality, 35:49
positron emission tomography, limbic system, 40:221
positron emission tomography, neuroleptics, 40:115
positron emission tomography, never-medicated patients, 40:135

Frontal lobe continued
positron emission tomography, obsessive-compulsive disorder, 40:221
positron emission tomography, prolactin, 40:101
positron emission tomography, schizophrenia, 40:101, 40:115, 40:135
positron emission tomography, State-Trait Anxiety Inventory, 35:49
positron emission tomography, temporal lobe, 40:135
prolactin, anxiety, 40:101
prolactin, glucose metabolism, 40:101
prolactin, homovanillic acid, 40:101
prolactin, positron emission tomography, 40:101
prolactin, schizophrenia, 40:101
schizophrenia, anxiety, 40:101
schizophrenia, apomorphine, 40:135
schizophrenia, basal ganglia, 40:115
schizophrenia, blood flow, 35:27, 40:253
schizophrenia, glucose metabolism, 40:101, 40:115, 40:135
schizophrenia, homovanillic acid, 40:101
schizophrenia, long-term followup, 40:253
schizophrenia, neuroleptics, 40:115
schizophrenia, never-medicated patients, 40:135
schizophrenia, positron emission tomography, 40:101, 40:115, 40:135
schizophrenia, prolactin, 40:101
schizophrenia, symptom severity, 35:27
schizophrenia, temporal lobe, 40:135
single photon emission computed tomography, affective disorder, 40:247
single photon emission computed tomography, hexamethylpropyleneamine-oxime (HMPAO), 40:247
single photon emission computed tomography, limbic system, 40:247
single photon emission computed tomography, sleep, 40:247
single photon emission computed tomography, sleep deprivation, 40:247
sleep, affective disorder, 40:247
sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep, limbic system, 40:247
sleep, single photon emission computed tomography, 40:247
sleep deprivation, affective disorder, 40:247
sleep deprivation, hexamethylpropylene-amineoxime (HMPAO), 40:247

Frontal lobe continued
sleep deprivation, limbic system, 40:247
sleep deprivation, single photon emission computed tomography, 40:247
State-Trait Anxiety Inventory, anxiety, 35:49
State-Trait Anxiety Inventory, glucose metabolism, 35:49
State-Trait Anxiety Inventory, laterality, 35:49
State-Trait Anxiety Inventory, positron emission tomography, 35:49
symptom severity, blood flow, 35:27
symptom severity, schizophrenia, 35:27
temporal lobe, apomorphine, 40:135
temporal lobe, glucose metabolism, 40:135
temporal lobe, never-medicated patients, 40:135
temporal lobe, positron emission tomography, 40:135
temporal lobe, schizophrenia, 40:135
Gadolinium-DTPA
blood-brain barrier, cortical sulcal enlargement, 40:203
blood-brain barrier, magnetic resonance imaging, 40:203
blood-brain barrier, schizophrenia, 40:203
blood-brain barrier, ventricular size, 40:203
cortical sulcal enlargement, blood-brain barrier, 40:203
cortical sulcal enlargement, magnetic resonance imaging, 40:203
cortical sulcal enlargement, schizophrenia, 40:203
cortical sulcal enlargement, ventricular size, 40:203
magnetic resonance imaging, blood-brain barrier, 40:203
magnetic resonance imaging, cortical sulcal enlargement, 40:203
magnetic resonance imaging, schizophrenia, 40:203
magnetic resonance imaging, ventricular size, 40:203
schizophrenia, blood-brain barrier, 40:203
schizophrenia, cortical sulcal enlargement, 40:203
schizophrenia, magnetic resonance imaging, 40:203
schizophrenia, ventricular size, 40:203
ventricular size, blood-brain barrier, 40:203
ventricular size, cortical sulcal enlargement, 40:203
ventricular size, magnetic resonance imaging, 40:203
ventricular size, schizophrenia, 40:203

Gender
hippocampus, schizophrenia, 35:1
schizophrenia, hippocampus, 35:1
Generalized anxiety disorder
blood flow, diazepam, 40:125
blood flow, ondansetron, 40:125
diazepam, blood flow, 40:125
diazepam, ondansetron, 40:125
ondansetron, blood flow, 40:125
ondansetron, diazepam, 40:125
Genetics
admixture analysis, computed tomography, 35:61
admixture analysis, schizophrenia, 35:61
admixture analysis, ventricle-brain ratio, 35:61
amygdala, hippocampus, 35:137
amygdala, magnetic resonance imaging, 35:137
amygdala, schizophrenia, 35:137
amygdala, temporal lobe, 35:137
amygdala, ventricular size, 35:137
computed tomography, admixture analysis, 35:61
computed tomography, schizophrenia, 35:61
computed tomography, ventricle-brain ratio, 35:61
cranial size, magnetic resonance imaging, 40:49
cranial size, schizophrenia, 40:49
cranial size, third ventricle, 40:49
cranial size, ventricular size, 40:49
hippocampus, amygdala, 35:137
hippocampus, magnetic resonance imaging, 35:137
hippocampus, schizophrenia, 35:137
hippocampus, temporal lobe, 35:137
hippocampus, ventricular size, 35:137
magnetic resonance imaging, amygdala, 35:137
magnetic resonance imaging, cranial size, 40:49
magnetic resonance imaging, hippocampus, 35:137
magnetic resonance imaging, schizophrenia, 35:137, 40:49
magnetic resonance imaging, temporal lobe, 35:137
magnetic resonance imaging, third ventricle, 40:49
magnetic resonance imaging, ventricular size, 35:137, 40:49
schizophrenia, admixture analysis, 35:61
schizophrenia, amygdala, 35:137
Genetics continued
schizophrenia, computed tomography, 35:61
schizophrenia, cranial size, 40:49
schizophrenia, hippocampus, 35:137
schizophrenia, magnetic resonance imaging, 35:137, 40:49
schizophrenia, temporal lobe, 35:137
schizophrenia, third ventricle, 40:49
schizophrenia, ventricle-brain ratio, 35:61
schizophrenia, ventricular size, 35:137, 40:49
temporal lobe, amygdala, 35:137
temporal lobe, hippocampus, 35:137
temporal lobe, magnetic resonance imaging, 35:137
temporal lobe, schizophrenia, 35:137
temporal lobe, ventricular size, 35:137
third ventricle, cranial size, 40:49
third ventricle, magnetic resonance imaging, 40:49
third ventricle, schizophrenia, 40:49
third ventricle, ventricular size, 40:49
ventricle-brain ratio, admixture analysis, 35:61
ventricle-brain ratio, computed tomography, 35:61
ventricle-brain ratio, schizophrenia, 35:61
ventricular size, amygdala, 35:137
ventricular size, cranial size, 40:49
ventricular size, hippocampus, 35:137
ventricular size, magnetic resonance imaging, 35:137, 40:49
ventricular size, schizophrenia, 35:137, 40:49
ventricular size, temporal lobe, 35:137
ventricular size, third ventricle, 40:49
Glucose metabolism
affective disorder, Alzheimer's disease, 40:195
affective disorder, frontal lobe, 40:195
affective disorder, hippocampus, 40:195
affective disorder, positron emission tomography, 40:195
Alzheimer's disease, affective disorder, 40:195
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, hippocampus, 40:195
Alzheimer's disease, positron emission tomography, 40:195
anxiety, frontal lobe, 35:49, 40:101
anxiety, homovanillic acid, 40:101
anxiety, laterality, 35:49
anxiety, positron emission tomography, 35:49, 40:101
anxiety, prolactin, 40:101
anxiety, schizophrenia, 40:101
anxiety, State-Trait Anxiety Inventory, 35:49

Glucose metabolism continued
apomorphine, frontal lobe, 40:135
apomorphine, never-medicated patients, 40:135
apomorphine, positron emission tomography, 40:135
apomorphine, schizophrenia, 40:135
apomorphine, temporal lobe, 40:135
basal ganglia, frontal lobe, 40:115
basal ganglia, neuroleptics, 40:115
basal ganglia, positron emission tomography, 40:115
basal ganglia, schizophrenia, 40:115
correlation analysis, frontal lobe, 40:221
correlation analysis, limbic system, 40:221
correlation analysis, obsessive-compulsive disorder, 40:221
correlation analysis, positron emission tomography, 40:221
ethanol, positron emission tomography, 35:39
frontal lobe, affective disorder, 40:195
frontal lobe, Alzheimer's disease, 40:195
frontal lobe, anxiety, 35:49, 40:101
frontal lobe, apomorphine, 40:135
frontal lobe, basal ganglia, 40:115
frontal lobe, correlation analysis, 40:221
frontal lobe, hippocampus, 40:195
frontal lobe, homovanillic acid, 40:101
frontal lobe, laterality, 35:49
frontal lobe, limbic system, 40:221
frontal lobe, neuroleptics, 40:115
frontal lobe, never-medicated patients, 40:135
frontal lobe, obsessive-compulsive disorder, 40:221
frontal lobe, positron emission tomography, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
frontal lobe, prolactin, 40:101
frontal lobe, schizophrenia, 40:101, 40:115, 40:135
frontal lobe, State-Trait Anxiety Inventory, 35:49
frontal lobe, temporal lobe, 40:135
hippocampus, affective disorder, 40:195
hippocampus, Alzheimer's disease, 40:195
hippocampus, frontal lobe, 40:195
hippocampus, positron emission tomography, 40:195
homovanillic acid, anxiety, 40:101
homovanillic acid, frontal lobe, 40:101
homovanillic acid, positron emission tomography, 40:101

Glucose metabolism, continued
homovanillic acid, prolactin, 40:101
homovanillic acid, schizophrenia, 40:101
laterality, anxiety, 35:49
laterality, frontal lobe, 35:49
laterality, positron emission tomography, 35:49
laterality, State-Trait Anxiety Inventory, 35:49
limbic system, correlation analysis, 40:221
limbic system, frontal lobe, 40:221
limbic system, obsessive-compulsive disorder, 40:221
limbic system, positron emission tomography, 40:221
measurement reliability, positron emission tomography, 40:11
measurement reliability, relative vs. absolute metabolic rate, 40:11
measurement reliability, schizophrenia, 40:11
neuroleptics, basal ganglia, 40:115
neuroleptics, frontal lobe, 40:115
neuroleptics, positron emission tomography, 40:115
neuroleptics, schizophrenia, 40:115
never-medicated patients, apomorphine, 40:135
never-medicated patients, frontal lobe, 40:135
never-medicated patients, positron emission tomography, 40:135
never-medicated patients, schizophrenia, 40:135
never-medicated patients, temporal lobe, 40:135
obsessive-compulsive disorder, correlation analysis, 40:221
obsessive-compulsive disorder, frontal lobe, 40:221
obsessive-compulsive disorder, limbic system, 40:221
obsessive-compulsive disorder, positron emission tomography, 40:221
positron emission tomography, affective disorder, 40:195
positron emission tomography, Alzheimer's disease, 40:195
positron emission tomography, anxiety, 35:49, 40:101
positron emission tomography, apomorphine, 40:135
positron emission tomography, basal ganglia, 40:115

Glucose metabolism continued
positron emission tomography, correlation analysis, 40:221
positron emission tomography, ethanol, 35:39
positron emission tomography, frontal lobe, 35:49, 40:101, 40:115, 40:195, 40:221
positron emission tomography, hippocampus, 40:195
positron emission tomography, homovanillic acid, 40:101
positron emission tomography, laterality, 35:49
positron emission tomography, limbic system, 40:221
positron emission tomography, measurement reliability, 40:11
positron emission tomography, neuroleptics, 40:115
positron emission tomography, never-medicated patients, 40:135
positron emission tomography, obsessive-compulsive disorder, 40:221
positron emission tomography, prolactin, 40:101
positron emission tomography, relative vs. absolute metabolic rate, 40:11
positron emission tomography, schizophrenia, 40:11, 40:101, 40:115, 40:135
positron emission tomography, State-Trait Anxiety Inventory, 35:49
positron emission tomography, temporal lobe, 40:135
positron emission tomography, tetrahydrocannabinol, 40:69
prolactin, anxiety, 40:101
prolactin, frontal lobe, 40:101
prolactin, homovanillic acid, 40:101
prolactin, positron emission tomography, 40:101
prolactin, schizophrenia, 40:101
relative vs. absolute metabolic rate, measurement reliability, 40:11
relative vs. absolute metabolic rate, positron emission tomography, 40:11
relative vs. absolute metabolic rate, schizophrenia, 40:11
schizophrenia, anxiety, 40:101
schizophrenia, apomorphine, 40:135
schizophrenia, basal ganglia, 40:115
schizophrenia, frontal lobe, 40:101, 40:115, 40:135
schizophrenia, homovanillic acid, 40:101
Glucose metabolism continued
schizophrenia, measurement reliability, 40:11
schizophrenia, neuroleptics, 40:115
schizophrenia, never-medicated patients, 40:135
schizophrenia, positron emission tomography, 40:11, 40:101, 40:115, 40:135
schizophrenia, prolactin, 40:101
schizophrenia, relative vs. absolute metabolic rate, 40:11
schizophrenia, temporal lobe, 40:135
State-Trait Anxiety Inventory, anxiety, 35:49
State-Trait Anxiety Inventory, frontal lobe, 35:49
State-Trait Anxiety Inventory, laterality, 35:49
State-Trait Anxiety Inventory, positron emission tomography, 35:49
temporal lobe, apomorphine, 40:135
temporal lobe, frontal lobe, 40:135
temporal lobe, never-medicated patients, 40:135
temporal lobe, positron emission tomography, 40:135
temporal lobe, schizophrenia, 40:135
tetrahydrocannabinol, positron emission tomography, 40:69
Haloperidol
positron emission tomography, schizophrenia, 40:115
schizophrenia, positron emission tomography, 40:115
Hippocampus
affective disorder, Alzheimer's disease, 40:195
affective disorder, frontal lobe, 40:195
affective disorder, glucose metabolism, 40:195
affective disorder, positron emission tomography, 40:195
aging, limbic system, 35:15
aging, magnetic resonance imaging, 35:15
aging, ventricular size, 35:15
Alzheimer's disease, affective disorder, 40:195
Alzheimer's disease, astrocytosis, 35:149
Alzheimer's disease, dentate gyrus, 35:149
Alzheimer's disease, entorhinal cortex, 35:149
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, glucose metabolism, 40:195
Alzheimer's disease, positron emission tomography, 40:195

Hippocampus continued
Alzheimer's disease, post-mortem examination, 35:149
Alzheimer's disease, schizophrenia, 35:149
amygdala, genetics, 35:137
amygdala, magnetic resonance imaging, 35:1, 35:137
amygdala, schizophrenia, 35:1, 35:137
amygdala, temporal horn volume, 35:1
amygdala, temporal lobe, 35:1, 35:137
amygdala, ventricular size, 35:137
astrocytosis, Alzheimer's disease, 35:149
astrocytosis, dentate gyrus, 35:149
astrocytosis, entorhinal cortex, 35:149
astrocytosis, post-mortem examination, 35:149
astrocytosis, schizophrenia, 35:149
dentate gyrus, Alzheimer's disease, 35:149
dentate gyrus, astrocytosis, 35:149
dentate gyrus, entorhinal cortex, 35:149
dentate gyrus, post-mortem examination, 35:149
dentate gyrus, schizophrenia, 35:149
entorhinal cortex, Alzheimer's disease, 35:149
entorhinal cortex, astrocytosis, 35:149
entorhinal cortex, dentate gyrus, 35:149
entorhinal cortex, post-mortem examination, 35:149
entorhinal cortex, schizophrenia, 35:149
frontal lobe, affective disorder, 40:195
frontal lobe, Alzheimer's disease, 40:195
frontal lobe, glucose metabolism, 40:195
frontal lobe, positron emission tomography, 40:195
gender, schizophrenia, 35:1
genetics, amygdala, 35:137
genetics, magnetic resonance imaging, 35:137
genetics, schizophrenia, 35:137
genetics, temporal lobe, 35:137
genetics, ventricular size, 35:137
glucose metabolism, affective disorder, 40:195
glucose metabolism, Alzheimer's disease, 40:195
glucose metabolism, frontal lobe, 40:195
glucose metabolism, positron emission tomography, 40:195
limbic system, aging, 35:15
limbic system, magnetic resonance imaging, 35:15
limbic system, ventricular size, 35:15
magnetic resonance imaging, aging, 35:15

Hippocampus continued
magnetic resonance imaging, amygdala, 35:1, 35:137
magnetic resonance imaging, genetics, 35:137
magnetic resonance imaging, limbic system, 35:15
magnetic resonance imaging, schizophrenia, 35:1, 35:137
magnetic resonance imaging, temporal horn volume, 35:1
magnetic resonance imaging, temporal lobe, 35:1, 35:137
magnetic resonance imaging, ventricular size, 35:15, 35:137
positron emission tomography, affective disorder, 40:195
positron emission tomography, Alzheimer's disease, 40:195
positron emission tomography, frontal lobe, 40:195
positron emission tomography, glucose metabolism, 40:195
post-mortem examination, Alzheimer's disease, 35:149
post-mortem examination, astrocytosis, 35:149
post-mortem examination, dentate gyrus, 35:149
post-mortem examination, entorhinal cortex, 35:149
post-mortem examination, schizophrenia, 35:149
schizophrenia, Alzheimer's disease, 35:149
schizophrenia, amygdala, 35:1, 35:137
schizophrenia, astrocytosis, 35:149
schizophrenia, dentate gyrus, 35:149
schizophrenia, entorhinal cortex, 35:149
schizophrenia, gender, 35:1
schizophrenia, genetics, 35:137
schizophrenia, magnetic resonance imaging, 35:1, 35:137
schizophrenia, post-mortem examination, 35:149
schizophrenia, temporal horn volume, 35:1
schizophrenia, temporal lobe, 35:1, 35:137
schizophrenia, ventricular size, 35:137
temporal horn volume, amygdala, 35:1
temporal horn volume, magnetic resonance imaging, 35:1
temporal horn volume, schizophrenia, 35:1
temporal horn volume, temporal lobe, 35:1
temporal lobe, amygdala, 35:1, 35:137
temporal lobe, genetics, 35:137

Hippocampus continued
temporal lobe, magnetic resonance imaging, 35:1, 35:137
temporal lobe, schizophrenia, 35:1, 35:137
temporal lobe, temporal horn volume, 35:1
temporal lobe, ventricular size, 35:137
ventricular size, aging, 35:15
ventricular size, amygdala, 35:137
ventricular size, genetics, 35:137
ventricular size, limbic system, 35:15
ventricular size, magnetic resonance imaging, 35:15, 35:137
ventricular size, schizophrenia, 35:137
ventricular size, temporal lobe, 35:137
HMPAO (Hexamethylproplyeneamine-oxime)
affective disorder, frontal lobe, 40:247
affective disorder, limbic system, 40:247
affective disorder, single photon emission computed tomography, 40:247
affective disorder, sleep, 40:247
affective disorder, sleep deprivation, 40:247
frontal lobe, affective disorder, 40:247
frontal lobe, limbic system, 40:247
frontal lobe, single photon emission computed tomography, 40:247
frontal lobe, sleep, 40:147
frontal lobe, sleep deprivation, 40:247
limbic system, affective disorder, 40:247
limbic system, frontal lobe, 40:247
limbic system, single photon emission computed tomography, 40:247
limbic system, sleep, 40:247
limbic system, sleep deprivation, 40:247
single photon emission computed tomography, affective disorder, 40:247
single photon emission computed tomography, frontal lobe, 40:247
single photon emission computed tomography, limbic system, 40:247
single photon emission computed tomography, sleep, 40:247
single photon emission computed tomography, sleep deprivation, 40:247
sleep, affective disorder, 40:247
sleep, frontal lobe, 40:247
sleep, limbic system, 40:247
sleep, single photon emission computed tomography, 40:247
sleep deprivation, affective disorder, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, limbic system, 40:247
sleep deprivation, single photon emission computed tomography, 40:247
Homovanillic acid
anxiety, frontal lobe, 40:101
anxiety, glucose metabolism, 40:101
anxiety, positron emission tomography, 40:101
anxiety, prolactin, 40:101
anxiety, schizophrenia, 40:101
frontal lobe, anxiety, 40:101
frontal lobe, glucose metabolism, 40:101
frontal lobe, positron emission tomography, 40:101
frontal lobe, prolactin, 40:101
frontal lobe, schizophrenia, 40:101
glucose metabolism, anxiety, 40:101
glucose metabolism, frontal lobe, 40:101
glucose metabolism, positron emission tomography, 40:101
glucose metabolism, prolactin, 40:101
glucose metabolism, schizophrenia, 40:101
positron emission tomography, anxiety, 40:101
positron emission tomography, frontal lobe, 40:101
positron emission tomography, glucose metabolism, 40:101
positron emission tomography, prolactin, 40:101
positron emission tomography, schizophrenia, 40:101
prolactin, anxiety, 40:101
prolactin, frontal lobe, 40:101
prolactin, glucose metabolism, 40:101
prolactin, positron emission tomography, 40:101
prolactin, schizophrenia, 40:101
schizophrenia, anxiety, 40:101
schizophrenia, frontal lobe, 40:101
schizophrenia, glucose metabolism, 40:101
schizophrenia, positron emission tomography, 40:101
schizophrenia, prolactin, 40:101
Human immunodeficiency virus
brain size, magnetic resonance imaging, 40:61
magnetic resonance imaging, brain size, 40:61
Laterality
anxiety, frontal lobe, 35:49
anxiety, glucose metabolism, 35:49
anxiety, positron emission tomography, 35:49
anxiety, State-Trait Anxiety Inventory, 35:49
cerebral asymmetry, computed tomography, 35:71

Laterality continued
cerebral asymmetry, measurement methods, 35:71
clomipramine, electroencephalographic topography, 40:91
clomipramine, evoked potentials, 40:91
clomipramine, fluoxetine, 40:91
clomipramine, P300, 40:91
clomipramine, serotonin, 40:91
computed tomography, cerebral asymmetry, 35:71
computed tomography, measurement methods, 35:71
electroencephalographic topography, clomipramine, 40:91
electroencephalographic topography, evoked potentials, 40:91
electroencephalographic topography, fluoxetine, 40:91
electroencephalographic topography, P300, 40:91
electroencephalographic topography, serotonin, 40:91
evoked potentials, clomipramine, 40:91
evoked potentials, electroencephalographic topography, 40:91
evoked potentials, fluoxetine, 40:91
evoked potentials, P300, 40:91
evoked potentials, serotonin, 40:91
fluoxetine, clomipramine, 40:91
fluoxetine, electroencephalographic topography, 40:91
fluoxetine, evoked potentials, 40:91
fluoxetine, P300, 40:91
fluoxetine, serotonin, 40:91
frontal lobe, anxiety, 35:49
frontal lobe, glucose metabolism, 35:49
frontal lobe, positron emission tomography, 35:49
frontal lobe, State-Trait Anxiety Inventory, 35:49
glucose metabolism, anxiety, 35:49
glucose metabolism, frontal lobe, 35:49
glucose metabolism, positron emission tomography, 35:49
glucose metabolism, State-Trait Anxiety Inventory, 35:49
measurement methods, cerebral asymmetry, 35:71
measurement methods, computed tomography, 35:71
P300, clomipramine, 40:91
P300, electroencephalographic topography, 40:91
P300, evoked potentials, 40:91
Laterality continued
P300, fluoxetine, 40:91
P300, serotonin, 40:91
positron emission tomography, anxiety, 35:49
positron emission tomography, frontal lobe, 35:49
positron emission tomography, glucose metabolism, 35:49
positron emission tomography, State-Trait Anxiety Inventory, 35:49
serotonin, clomipramine, 40:91
serotonin, electroencephalographic topography, 40:91
serotonin, evoked potentials, 40:91
serotonin, fluoxetine, 40:91
serotonin, P300, 40:91
State-Trait Anxiety Inventory, anxiety, 35:49
State-Trait Anxiety Inventory, frontal lobe, 35:49
State-Trait Anxiety Inventory, glucose metabolism, 35:49
State-Trait Anxiety Inventory, positron emission tomography, 35:49
Limbic system
affective disorder, basal ganglia, 40:95
affective disorder, frontal lobe, 40:247
affective disorder, hexamethylpropylene-amineoxime (HMPAO), 40:247
affective disorder, magnetic resonance imaging, 40:95
affective disorder, putamen, 40:95
affective disorder, single photon emission computed tomography, 40:247
affective disorder, sleep, 40:247
affective disorder, sleep deprivation, 40:247
aging, hippocampus, 35:15
aging, magnetic resonance imaging, 35:15
aging, ventricular size, 35:15
basal ganglia, affective disorder, 40:95
basal ganglia, magnetic resonance imaging, 40:95
basal ganglia, putamen, 40:95
correlation analysis, frontal lobe, 40:221
correlation analysis, glucose metabolism, 40:221
correlation analysis, obsessive-compulsive disorder, 40:221
correlation analysis, positron emission tomography, 40:221
frontal lobe, affective disorder, 40:247
frontal lobe, correlation analysis, 40:221
frontal lobe, glucose metabolism, 40:221

Limbic system continued
frontal lobe, hexamethylpropyleneamine-oxime (HMPAO), 40:247
frontal lobe, obsessive-compulsive disorder, 40:221
frontal lobe, positron emission tomography, 40:221
frontal lobe, single photon emission computed tomography, 40:247
frontal lobe, sleep, 40:247
frontal lobe, sleep deprivation, 40:247
glucose metabolism, correlation analysis, 40:221
glucose metabolism, frontal lobe, 40:221
glucose metabolism, obsessive-compulsive disorder, 40:221
glucose metabolism, positron emission tomography, 40:221
hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
hippocampus, aging, 35:15
hippocampus, magnetic resonance imaging, 35:15
hippocampus, ventricular size, 35:15
magnetic resonance imaging, affective disorder, 40:95
magnetic resonance imaging, aging, 35:15
magnetic resonance imaging, basal ganglia, 40:95
magnetic resonance imaging, hippocampus, 35:15
magnetic resonance imaging, putamen, 40:95
magnetic resonance imaging, ventricular size, 35:15
obsessive-compulsive disorder, correlation analysis, 40:247
obsessive-compulsive disorder, frontal lobe, 40:247
obsessive-compulsive disorder, glucose metabolism, 40:247
obsessive-compulsive disorder, positron emission tomography, 40:221
positron emission tomography, correlation analysis, 40:221
positron emission tomography, frontal lobe, 40:221

Limbic system continued
positron emission tomography, glucose metabolism, 40:221
positron emission tomography, obsessive-compulsive disorder, 40:221
putamen, affective disorder, 40:95
putamen, basal ganglia, 40:95
putamen, magnetic resonance imaging, 40:95
single photon emission computed tomography, affective disorder, 40:247
single photon emission computed tomography, frontal lobe, 40:247
single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247
single photon emission computed tomography, sleep, 40:247
single photon emission computed tomography, sleep deprivation, 40:247
sleep, affective disorder, 40:247
sleep deprivation, affective disorder, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep deprivation, single photon emission computed tomography, 40:247
sleep, frontal lobe, 40:247
sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep, single photon emission computed tomography, 40:247
ventricular size, aging, 35:15
ventricular size, hippocampus, 35:15
ventricular size, magnetic resonance imaging, 35:15
Locus ceruleus
brain stem reticular formation, neuropathology, 40:31
brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
brain stem reticular formation, pedunculopontine nucleus, 40:31
brain stem reticular formation, schizophrenia, 40:31
neuropathology, brain stem reticular formation, 40:31
neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
neuropathology, pedunculopontine nucleus, 40:31
neuropathology, schizophrenia, 40:31
nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31

Locus ceruleus continued
nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
pedunculopontine nucleus, brain stem reticular formation, 40:31
pedunculopontine nucleus, neuropathology, 40:31
pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
pedunculopontine nucleus, schizophrenia, 40:31
schizophrenia, brain stem reticular formation, 40:31
schizophrenia, neuropathology, 40:31
schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
schizophrenia, pedunculopontine nucleus, 40:31
Magnetic resonance imaging
affective disorder, aging, 40:211
affective disorder, basal ganglia, 40:95
affective disorder, late onset, 40:211
affective disorder, limbic system, 40:95
affective disorder, mania, 40:211
affective disorder, putamen, 40:95
affective disorder, subcortical hyperintensities, 40:211
aging, affective disorder, 40:211
aging, hippocampus, 35:15
aging, late onset, 40:211
aging, limbic system, 35:15
aging, mania, 40:211
aging, subcortical hyperintensities, 40:211
aging, ventricular size, 35:15
amygdala, genetics, 35:137
amygdala, hippocampus, 35:1, 35:137
amygdala, schizophrenia, 35:1, 35:137
amygdala, temporal horn volume, 35:1
amygdala, temporal lobe, 35:1, 35:137
amygdala, ventricular size, 35:137
basal ganglia, affective disorder, 40:95
basal ganglia, limbic system, 40:95
basal ganglia, putamen, 40:95
basal ganglia, schizophrenia, 40:157
basal ganglia, tardive dyskinesia, 40:157
blood-brain barrier, cortical sulcal enlargement, 40:203
blood-brain barrier, gadolinium-DPTA, 40:203
Magnetic resonance imaging continued
blood-brain barrier, schizophrenia, 40:203
blood-brain barrier, ventricular size, 40:203
brain volume, computer methods, 40:61
computer methods, brain volume, 40:61
cortical sulcal enlargement, blood-brain barrier, 40:203
cortical sulcal enlargement, gadolinium-DPTA, 40:203
cortical sulcal enlargement, schizophrenia, 40:203
cortical sulcal enlargement, ventricular size, 40:203
cranial size, genetics, 40:49
cranial size, schizophrenia, 40:49
cranial size, third ventricle, 40:49
cranial size, ventricular size, 40:49
fluorinated neuroleptics, spectroscopy, 35:107
fluphenazine, pharmacokinetics, 35:107
fluphenazine, schizophrenia, 35:107
gadolinium-DPTA, blood-brain barrier, 40:203
gadolinium-DPTA, cortical sulcal enlargement, 40:203
gadolinium-DPTA, schizophrenia, 40:203
gadolinium-DPTA, ventricular size, 40:203
genetics, amygdala, 35:137
genetics, cranial size, 40:49
genetics, hippocampus, 35:137
genetics, schizophrenia, 35:137, 40:49
genetics, temporal lobe, 35:137
genetics, third ventricle, 40:49
genetics, ventricular size, 35:137, 40:49
hippocampus, aging, 35:15
hippocampus, amygdala, 35:1, 35:137
hippocampus, genetics, 35:137
hippocampus, limbic system, 35:15
hippocampus, schizophrenia, 35:1, 35:137
hippocampus, temporal horn volume, 35:1
hippocampus, temporal lobe, 35:1, 35:137
hippocampus, ventricular size, 35:15, 35:137
late onset, affective disorder, 40:211
late onset, aging, 40:211
late onset, mania, 40:211
late onset, subcortical hyperintensities, 40:211
limbic system, affective disorder, 40:95
limbic system, aging, 35:15
limbic system, basal ganglia, 40:95
limbic system, hippocampus, 35:15
limbic system, putamen, 40:95
limbic system, ventricular size, 35:15
mania, aging, 40:211

Magnetic resonance imaging continued
mania, late onset, 40:211
mania, subcortical hyperintensities, 40:wm
pharmacokinetics, fluphenazine, 35:107
pharmacokinetics, schizophrenia, 35:107
putamen, affective disorder, 40:95
putamen, basal ganglia, 40:95
putamen, limbic system, 40:95
ratio measurement reliability, ventricle-brain ratio, 40:79
schizophrenia, amygdala, 35:1, 35:137
schizophrenia, basal ganglia, 40:157
schizophrenia, blood-brain barrier, 40:203
schizophrenia, cortical sulcal enlargement, 40:203
schizophrenia, cranial size, 40:49
schizophrenia, fluphenazine, 35:107
schizophrenia, gadolinium-DPTA, 40:203
schizophrenia, genetics, 35:137, 40:49
schizophrenia, hippocampus, 35:1, 35:137
schizophrenia, pharmacokinetics, 35:107
schizophrenia, T2 hyperintense foci, 40:239
schizophrenia, tardive dyskinesia, 40:157, 40:239
schizophrenia, temporal horn volume, 35:1
schizophrenia, temporal lobe, 35:1, 35:137
schizophrenia, third ventricle, 40:49
schizophrenia, ventricular size, 35:137, 40:49, 40:203
spectroscopy, fluorinated neuroleptics, 35:107
subcortical hyperintensities, affective disorder, 40:211
subcortical hyperintensities, aging, 40:211
subcortical hyperintensities, late onset, 40:211
subcortical hyperintensities, mania, 40:211
T2 hyperintense foci, schizophrenia, 40:239
T2 hyperintense foci, tardive dyskinesia, 40:239
tardive dyskinesia, basal ganglia, 40:157
tardive dyskinesia, schizophrenia, 40:157, 40:239
tardive dyskinesia, T2 hyperintense foci, 40:239
temporal horn volume, amygdala, 35:1
temporal horn volume, hippocampus, 35:1
temporal horn volume, schizophrenia, 35:1
temporal horn volume, temporal lobe, 35:1
temporal lobe, amygdala, 35:1, 35:137
temporal lobe, genetics, 35:137
temporal lobe, hippocampus, 35:1, 35:137
temporal lobe, schizophrenia, 35:1, 35:137
temporal lobe, temporal horn volume, 35:1

Magnetic resonance imaging continued
temporal lobe, ventricular size, 35:137
third ventricle, cranial size, 40:49
third ventricle, genetics, 40:49
third ventricle, schizophrenia, 40:49
third ventricle, ventricular size, 40:49
ventricle-brain ratio, ratio measurement reliability, 40:79
ventricular size, aging, 35:15
ventricular size, amygdala, 35:137
ventricular size, blood-brain barrier, 40:203
ventricular size, cortical sulcal enlargement, 40:203
ventricular size, cranial size, 40:49
ventricular size, gadolinium-DPTA, 40:203
ventricular size, genetics, 35:137, 40:49
ventricular size, hippocampus, 35:137, 35:15
ventricular size, limbic system, 35:15
ventricular size, schizophrenia, 35:137, 40:49, 40:203
ventricular size, temporal lobe, 35:137
ventricular size, third ventricle, 40:49
Neuroleptics
basal ganglia, frontal lobe, 40:115
basal ganglia, glucose, 40:115
basal ganglia, positron emission tomography, 40:115
basal ganglia, schizophrenia, 40:115
frontal lobe, basal ganglia, 40:115
frontal lobe, glucose, 40:115
frontal lobe, positron emission tomography, 40:115
frontal lobe, schizophrenia, 40:115
glucose, basal ganglia, 40:115
glucose, frontal lobe, 40:115
glucose, positron emission tomography, 40:115
glucose, schizophrenia, 40:115
positron emission tomography, basal ganglia, 40:115
positron emission tomography, frontal lobe, 40:115
positron emission tomography, glucose, 40:115
positron emission tomography, schizophrenia, 40:115
schizophrenia, basal ganglia, 40:115
schizophrenia, frontal lobe, 40:115
schizophrenia, glucose, 40:115
schizophrenia, positron emission tomography, 40:115
Neuropathology
Alzheimer's disease, astrocytosis, 35:149
Alzheimer's disease, schizophrenia, 35:149

Neuropathology continued
astrocytosis, Alzheimer's disease, 35:149
astrocytosis, schizophrenia, 35:149
brain stem reticular formation, locus ceruleus, 40:31
brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
brain stem reticular formation, pedunculopontine nucleus, 40:31
brain stem reticular formation, schizophrenia, 40:31
locus ceruleus, brain stem reticular formation, 40:31
locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
locus ceruleus, pedunculopontine nucleus, 40:31
locus ceruleus, schizophrenia, 40:31
nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
pedunculopontine nucleus, brain stem reticular formation, 40:31
pedunculopontine nucleus, locus ceruleus, 40:31
pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
pedunculopontine nucleus, schizophrenia, 40:31
schizophrenia, Alzheimer's disease, 35:149
schizophrenia, astrocytosis, 35:149
schizophrenia, brain stem reticular formation, 40:31
schizophrenia, locus ceruleus, 40:31
schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
schizophrenia, pedunculopontine nucleus, 40:31
Neuropsychology
Alzheimer's disease, computed tomography, 35:115
Alzheimer's disease, electroencephalographic topography, 40:181
Alzheimer's disease, severity of dementia, 40:181
blood flow, Chicago Word Fluency Test, 40:253
Neuropsychology continued
blood flow, schizophrenia, 40:253
blood flow, Wisconsin Card Sort Test, 40:253
Chicago Word Fluency Test, blood flow, 40:253
computed tomography, Alzheimer's disease, 35:115
electroencephalographic topography, Alzheimer's disease, 40:181
electroencephalographic topography, severity of dementia, 40:181
schizophrenia, blood flow, 40:253
schizophrenia, Wisconsin Card Sort Test, 40:253
severity of dementia, Alzheimer's disease, 40:181
severity of dementia, electroencephalographic topography, 40:181
Wisconsin Card Sort Test, blood flow, 40:253
Wisconsin Card Sort Test, schizophrenia, 40:253
Nicotinamide adenosine dinucleotide phosphate-diaphorase histochemistry
brain stem reticular formation, locus ceruleus, 40:31
brain stem reticular formation, neuropathology, 40:31
brain stem reticular formation, pedunculopontine nucleus, 40:31
brain stem reticular formation, schizophrenia, 40:31
locus ceruleus, brain stem reticular formation, 40:31
locus ceruleus, neuropathology, 40:31
locus ceruleus, pedunculopontine nucleus, 40:31
locus ceruleus, schizophrenia, 40:31
neuropathology, brain stem reticular formation, 40:31
neuropathology, locus ceruleus, 40:31
neuropathology, pedunculopontine nucleus, 40:31
neuropathology, schizophrenia, 40:31
pedunculopontine nucleus, brain stem reticular formation, 40:31
pedunculopontine nucleus, locus ceruleus, 40:31
pedunculopontine nucleus, neuropathology, 40:31
pedunculopontine nucleus, schizophrenia, 40:31
post-mortem, schizophrenia, 40:31

Nicotinamide adenosine dinucleotide phosphate-diaphorase histochemistry continued
schizophrenia, brain stem reticular formation, 40:31
schizophrenia, locus ceruleus, 40:31
schizophrenia, neuropathology, 40:31
schizophrenia, pedunculopontine nucleus, 40:31
schizophrenia, post-mortem, 40:31
Obsessive-compulsive disorder
brain size, magnetic resonance imaging, 40:61
correlation analysis, frontal lobe, 40:221
correlation analysis, glucose metabolism, 40:221
correlation analysis, limbic system, 40:221
correlation analysis, positron emission tomography, 40:221
frontal lobe, correlation analysis, 40:221
frontal lobe, glucose metabolism, 40:221
frontal lobe, limbic system, 40:221
frontal lobe, positron emission tomography, 40:221
glucose metabolism, correlation analysis, 40:221
glucose metabolism, frontal lobe, 40:221
glucose metabolism, limbic system, 40:221
glucose metabolism, positron emission tomography, 40:221
limbic system, correlation analysis, 40:221
limbic system, frontal lobe, 40:221
limbic system, glucose metabolism, 40:221
limbic system, positron emission tomography, 40:221
magnetic resonance imaging, brain size, 40:61
positron emission tomography, correlation analysis, 40:221
positron emission tomography, frontal lobe, 40:221
positron emission tomography, glucose metabolism, 40:221
positron emission tomography, limbic system, 40:221
Ondansetron
anxiety, blood flow, 40:125
anxiety, diazepam, 40:125
anxiety, generalized anxiety disorder, 40:125
blood flow, anxiety, 40:125
blood flow, diazepam, 40:125
blood flow, generalized anxiety disorder, 40:125
diazepam, anxiety, 40:125
diazepam, blood flow, 40:125
diazepam, generalized anxiety disorder,40:125
generalized anxiety disorder, anxiety, 40:125
Ondansetron continued
generalized anxiety disorder, blood flow, 40:125
generalized anxiety disorder, diazepam, 40:125
Pedunculopontine nucleus
brain stem reticular formation, locus ceruleus, 40:31
brain stem reticular formation, neuropathology, 40:31
brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
brain stem reticular formation, schizophrenia, 40:31
locus ceruleus, brain stem reticular formation, 40:31
locus ceruleus, neuropathology, 40:31
locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
locus ceruleus, schizophrenia, 40:31
neuropathology, brain stem reticular formation, 40:31
neuropathology, locus ceruleus, 40:31
neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
neuropathology, schizophrenia, 40:31
nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
schizophrenia, brain stem reticular formation, 40:31
schizophrenia, locus ceruleus, 40:31
schizophrenia, neuropathology, 40:31
schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
Polysomnography
arecoline, electroencephalographic topography, 35:91
arecoline, sleep, 35:91
electroencephalographic topography, arecoline, 35:91
electroencephalographic topography, sleep, 35:91
sleep, arecoline, 35:91
sleep, electroencephalographic topography, 35:91
Positron emission tomography
affective disorder, Alzheimer's disease, 40:195

Positron emission tomography continued
affective disorder, frontal lobe, 40:195
affective disorder, glucose metabolism, 40:195
affective disorder, hippocampus, 40:195
Alzheimer's disease, affective disorder, 40:195
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, glucose metabolism, 40:195
Alzheimer's disease, hippocampus, 40:195
anxiety, frontal lobe, 35:49, 40:101
anxiety, glucose metabolism, 35:49, 40:101
anxiety, homovanillic acid, 40:101
anxiety, laterality, 35:49
anxiety, prolactin, 40:101
anxiety, schizophrenia, 40:101
anxiety, State-Trait Anxiety Inventory, 35:49
apomorphine, frontal lobe, 40:135
apomorphine, glucose metabolism, 40:135
apomorphine, never-medicated patients, 40:135
apomorphine, schizophrenia, 40:135
apomorphine, temporal lobe, 40:135
basal ganglia, glucose, 40:115
basal ganglia, neuroleptics, 40:115
basal ganglia, schizophrenia, 40:115
correlation analysis, frontal lobe, 40:221
correlation analysis, glucose metabolism, 40:221
correlation analysis, limbic system, 40:221
correlation analysis, obsessive-compulsive disorder, 40:221
ethanol, glucose metabolism, 35:39
frontal lobe, affective disorder, 40:195
frontal lobe, Alzheimer's disease, 40:195
frontal lobe, anxiety, 35:49, 40:101
frontal lobe, apomorphine, 40:135
frontal lobe, basal ganglia, 40:115
frontal lobe, correlation analysis, 40:221
frontal lobe, glucose, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
frontal lobe, homovanillic acid, 40:101
frontal lobe, laterality, 35:49
frontal lobe, limbic system, 40:221
frontal lobe, neuroleptics, 40:115
frontal lobe, never-medicated patients, 40:135
frontal lobe, obsessive-compulsive disorder, 40:221
frontal lobe, prolactin, 40:101
frontal lobe, schizophrenia, 40:101, 40:115, 40:135

Positron emission tomography continued
frontal lobe, State-Trait Anxiety Inventory, 35:49
glucose, basal ganglia, 40:115
glucose, frontal lobe, 40:115
glucose metabolism, affective disorder, 40:195
glucose metabolism, Alzheimer's disease, 40:195
glucose metabolism, anxiety, 35:49, 40:101
glucose metabolism, apomorphine, 40:135
glucose metabolism, correlation analysis, 40:221
glucose metabolism, ethanol, 35:39
glucose metabolism, frontal lobe, 35:49, 40:101, 40:135, 40:195, 40:221
glucose metabolism, hippocampus, 40:195
glucose metabolism, homovanillic acid, 40:101
glucose metabolism, laterality, 35:49
glucose metabolism, limbic system, 40:221
glucose metabolism, measurement reliability, 40:11
glucose metabolism, never-medicated patients, 40:135
glucose metabolism, obsessive-compulsive disorder, 40:221
glucose metabolism, prolactin, 40:101
glucose metabolism, relative vs. absolute metabolic rate, 40:11
glucose metabolism, schizophrenia, 40:11, 40:101, 40:135
glucose metabolism, State-Trait Anxiety Inventory, 35:49
glucose metabolism, temporal lobe, 40:135
glucose metabolism, tetrahydrocannabinol, 40:69
glucose, neuroleptics, 40:115
glucose, schizophrenia, 40:115
haloperidol, schizophrenia, 40:115
hippocampus, affective disorder, 40:195
hippocampus, Alzheimer's disease, 40:195
hippocampus, frontal lobe, 40:195
hippocampus, glucose metabolism, 40:195
homovanillic acid, anxiety, 40:101
homovanillic acid, frontal lobe, 40:101
homovanillic acid, glucose metabolism, 40:101
homovanillic acid, prolactin, 40:101
homovanillic acid, schizophrenia, 40:101
laterality, anxiety, 35:49
laterality, frontal lobe, 35:49
laterality, glucose metabolism, 35:49
laterality, State-Trait Anxiety Inventory, 35:49

Positron emission tomography continued
limbic system, correlation analysis, 40:221
limbic system, frontal lobe, 40:221
limbic system, glucose metabolism, 40:221
limbic system, obsessive-compulsive disorder, 40:221
measurement reliability, glucose metabolism, 40:11
measurement reliability, relative vs. absolute metabolic rate, 40:11
measurement reliability, schizophrenia, 40:11
neuroleptics, basal ganglia, 40:115
neuroleptics, frontal lobe, 40:115
neuroleptics, glucose, 40:115
neuroleptics, schizophrenia, 40:115
never-medicated patients, apomorphine, 40:135
never-medicated patients, frontal lobe, 40:135
never-medicated patients, glucose metabolism, 40:135
never-medicated patients, schizophrenia, 40:135
never-medicated patients, temporal lobe, 40:135
obsessive-compulsive disorder, correlation analysis, 40:221
obsessive-compulsive disorder, frontal lobe, 40:221
obsessive-compulsive disorder, glucose metabolism, 40:221
obsessive-compulsive disorder, limbic system, 40:221
prolactin, anxiety, 40:101
prolactin, frontal lobe, 40:101
prolactin, glucose metabolism, 40:101
prolactin, homovanillic acid, 40:101
prolactin, schizophrenia, 40:101
relative vs. absolute metabolic rate, glucose metabolism, 40:11
relative vs. absolute metabolic rate, measurement reliability, 40:11
relative vs. absolute metabolic rate, schizophrenia, 40:11
schizophrenia, anxiety, 40:101
schizophrenia, apomorphine, 40:135
schizophrenia, basal ganglia, 40:115
schizophrenia, frontal lobe, 40:101, 40:115, 40:135
schizophrenia, glucose metabolism, 40:11, 40:101, 40:135
schizophrenia, haloperidol, 40:115
schizophrenia, homovanillic acid, 40:101
Positron emission tomography continued
schizophrenia, measurement reliability, 40:11
schizophrenia, neuroleptics, 40:115
schizophrenia, never-medicated patients, 40:135
schizophrenia, prolactin, 40:101
schizophrenia, relative vs. absolute metabolic rate, 40:11
schizophrenia, temporal lobe, 40:135
schizophrenia, thiothixene, 40:115
State-Trait Anxiety Inventory, anxiety, 35:49
State-Trait Anxiety Inventory, frontal lobe, 35:49
State-Trait Anxiety Inventory, glucose metabolism, 35:49
State-Trait Anxiety Inventory, laterality, 35:49
temporal lobe, apomorphine, 40:135
temporal lobe, frontal lobe, 40:135
temporal lobe, glucose metabolism, 40:135
temporal lobe, never-medicated patients, 40:135
temporal lobe, schizophrenia, 40:135
tetrahydrocannabinol, glucose metabolism, 40:69
thiothixene, schizophrenia, 40:115
Post-mortem studies. See also Neuropathology
nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
Prolactin
anxiety, frontal lobe, 40:101
anxiety, glucose metabolism, 40:101
anxiety, homovanillic acid, 40:101
anxiety, positron emission tomography, 40:101
anxiety, schizophrenia, 40:101
frontal lobe, anxiety, 40:101
frontal lobe, glucose metabolism, 40:101
frontal lobe, homovanillic acid, 40:101
frontal lobe, positron emission tomography, 40:101
frontal lobe, schizophrenia, 40:101
glucose metabolism, anxiety, 40:101
glucose metabolism, frontal lobe, 40:101
glucose metabolism, homovanillic acid, 40:101
glucose metabolism, positron emission tomography, 40:101
glucose metabolism, schizophrenia, 40:101

Prolactin continued
homovanillic acid, anxiety, 40:101
homovanillic acid, frontal lobe, 40:101
homovanillic acid, glucose metabolism, 40:101
homovanillic acid, positron emission tomography, 40:101
homovanillic acid, schizophrenia, 40:101
positron emission tomography, anxiety, 40:101
positron emission tomography, frontal lobe, 40:101
positron emission tomography, glucose metabolism, 40:101
positron emission tomography, homovanillic acid, 40:101
positron emission tomography, schizophrenia, 40:101
schizophrenia, anxiety, 40:101
schizophrenia, frontal lobe, 40:101
schizophrenia, glucose metabolism, 40:101
schizophrenia, homovanillic acid, 40:101
schizophrenia, positron emission tomography, 40:101
Schizophrenia
admixture analysis, computed tomography, 35:61
admixture analysis, genetics, 35:61
admixture analysis, ventricle-brain ratio, 35:61
Alzheimer's disease, astrocytosis, 35:149
Alzheimer's disease, dentate gyrus, 35:149
Alzheimer's disease, entorhinal cortex, 35:149
Alzheimer's disease, hippocampus, 35:149
Alzheimer's disease, post-mortem examination, 35:149
amygdala, genetics, 35:137
amygdala, hippocampus, 35:1, 35:137
amygdala, magnetic resonance imaging, 35:1, 35:137
amygdala, temporal horn volume, 35:1
amygdala, temporal lobe, 35:1, 35:137
amygdala, ventricular size, 35:137
anxiety, frontal lobe, 40:101
anxiety, glucose metabolism, 40:101
anxiety, homovanillic acid, 40:101
anxiety, positron emission tomography, 40:101
anxiety, prolactin, 40:101
apomorphine, frontal lobe, 40:135
apomorphine, glucose metabolism, 40:135
apomorphine, never-medicated patients, 40:135
Schizophrenia continued
apomorphine, positron emission tomography, 40:135
apomorphine, temporal lobe, 40:135
astrocytosis, Alzheimer's disease, 35:149
astrocytosis, dentate gyrus, 35:149
astrocytosis, entorhinal cortex, 35:149
astrocytosis, hippocampus, 35:149
astrocytosis, post-mortem examination, 35:149
basal ganglia, frontal lobe, 40:115
basal ganglia, glucose, 40:115
basal ganglia, magnetic resonance imaging, 40:157
basal ganglia, neuroleptics, 40:115
basal ganglia, positron emission tomography, 40:115
basal ganglia, tardive dyskinesia, 40:157
blood-brain barrier, cortical sulcal enlargement, 40:203
blood-brain barrier, gadolinium-DPTA, 40:203
blood-brain barrier, magnetic resonance imaging, 40:203
blood-brain barrier, ventricular size, 40:203
blood flow, frontal lobe, 35:27, 40:253
blood flow, long-term followup, 40:253
blood flow, neuropsychology, 40:253
blood flow, symptom severity, 35:27
blood flow, Wisconsin Card Sort Test, 40:253
brain size, magnetic resonance imaging, 40:61
brain stem reticular formation, locus ceruleus, 40:31
brain stem reticular formation, neuropathology, 40:31
brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
brain stem reticular formation, pedunculopontine nucleus, 40:31
computed tomography, admixture analysis, 35:61
computed tomography, genetics, 35:61
computed tomography, stability after psychosis onset, 40:21
computed tomography, ventricle-brain ratio, 35:61
computed tomography, ventricular size, 40:21
cortical sulcal enlargement, blood-brain barrier, 40:203
cortical sulcal enlargement, gadolinium-DPTA, 40:203

Schizophrenia continued
cortical sulcal enlargement, magnetic resonance imaging, 40:203
cortical sulcal enlargement, ventricular size, 40:203
cranial size, genetics, 40:49
cranial size, magnetic resonance imaging, 40:49
cranial size, third ventricle, 40:49
cranial size, ventricular size, 40:49
dentate gyrus, Alzheimer's disease, 35:149
dentate gyrus, astrocytosis, 35:149
dentate gyrus, entorhinal cortex, 35:149
dentate gyrus, hippocampus, 35:149
dentate gyrus, post-mortem examination, 35:149
entorhinal cortex, Alzheimer's disease, 35:149
entorhinal cortex, astrocytosis, 35:149
entorhinal cortex, dentate gyrus, 35:149
entorhinal cortex, hippocampus, 35:149
entorhinal cortex, post-mortem examination, 35:149
fluphenazine, magnetic resonance spectroscopy, 35:107
fluphenazine, pharmacokinetics, 35:107
frontal lobe, anxiety, 40:101
frontal lobe, apomorphine, 40:135
frontal lobe, basal ganglia, 40:115
frontal lobe, blood flow, 35:27, 40:253
frontal lobe, glucose, 40:115
frontal lobe, glucose metabolism, 40:101, 40:135
frontal lobe, homovanillic acid, 40:101
frontal lobe, long-term followup, 40:253
frontal lobe, neuroleptics, 40:115
frontal lobe, never-medicated patients, 40:135
frontal lobe, positron emission tomography, 40:101, 40:115, 40:135
frontal lobe, prolactin, 40:101
frontal lobe, symptom severity, 35:27
frontal lobe, temporal lobe, 40:135
gadolinium-DPTA, blood-brain barrier, 40:203
gadolinium-DPTA, cortical sulcal enlargement, 40:203
gadolinium-DPTA, magnetic resonance imaging, 40:203
gadolinium-DPTA, ventricular size, 40:203
gender, hippocampus, 35:1
genetics, admixture analysis, 35:61
genetics, amygdala, 35:137
genetics, computed tomography, 35:61

Schizophrenia continued
genetics, cranial size, 40:49
genetics, hippocampus, 35:137
genetics, magnetic resonance imaging, 35:137, 40:49
genetics, temporal lobe, 35:137
genetics, third ventricle, 40:49
genetics, ventricle-brain ratio, 35:61
genetics, ventricular size, 35:137, 40:49
glucose, basal ganglia, 40:115
glucose, frontal lobe, 40:115
glucose metabolism, anxiety, 40:101
glucose metabolism, apomorphine, 40:135
glucose metabolism, frontal lobe, 40:101, 40:135
glucose metabolism, homovanillic acid, 40:101
glucose metabolism, measurement reliability, 40:11
glucose metabolism, never-medicated patients, 40:135
glucose metabolism, positron emission tomography, 40:11, 40:101, 40:135
glucose metabolism, prolactin, 40:101
glucose metabolism, relative vs. absolute metabolic rate, 40:11
glucose metabolism, temporal lobe, 40:135
glucose, neuroleptics, 40:115
glucose, positron emission tomography, 40:115
haloperidol, positron emission tomography, 40:115
hippocampus, Alzheimer's disease, 35:149
hippocampus, amygdala, 35:1, 35:137
hippocampus, astrocytosis, 35:149
hippocampus, dentate gyrus, 35:149
hippocampus, entorhinal cortex, 35:149
hippocampus, gender, 35:1
hippocampus, genetics, 35:137
hippocampus, magnetic resonance imaging, 35:1, 35:137
hippocampus, post-mortem examination, 35:149
hippocampus, temporal horn volume, 35:1
hippocampus, temporal lobe, 35:1, 35:137
hippocampus, ventricular size, 35:137
homovanillic acid, anxiety, 40:101
homovanillic acid, frontal lobe, 40:101
homovanillic acid, glucose metabolism, 40:101
homovanillic acid, positron emission tomography, 40:101
homovanillic acid, prolactin, 40:101
locus ceruleus, brain stem reticular formation, 40:31

Schizophrenia continued
locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
locus ceruleus, neuropathology, 40:31
locus ceruleus, pedunculopontine nucleus, 40:31
long-term followup, blood flow, 40:253
long-term followup, frontal lobe, 40:253
magnetic resonance imaging, amygdala, 35:1, 35:137
magnetic resonance imaging, basal ganglia, 40:157
magnetic resonance imaging, blood-brain barrier, 40:203
magnetic resonance imaging, brain size, 40:61
magnetic resonance imaging, cortical sulcal enlargement, 40:203
magnetic resonance imaging, cranial size, 40:49
magnetic resonance imaging, gadolinium-DPTA, 40:203
magnetic resonance imaging, genetics, 35:137, 40:49
magnetic resonance imaging, hippocampus, 35:1, 35:137
magnetic resonance imaging, T2 hyperintense foci, 40:239
magnetic resonance imaging, tardive dyskinesia, 40:157, 40:239
magnetic resonance imaging, temporal horn volume, 35:1
magnetic resonance imaging, temporal lobe, 35:1, 35:137
magnetic resonance imaging, third ventricle, 40:49
magnetic resonance imaging, ventricular size, 35:137, 40:49, 40:203
magnetic resonance spectroscopy, fluphenazine, 35:107
magnetic resonance spectroscopy, pharmacokinetics, 35:107
measurement reliability, glucose metabolism, 40:11
measurement reliability, positron emission tomography, 40:11
measurement reliability, relative vs. absolute metabolic rate, 40:11
neuroleptics, basal ganglia, 40:115
neuroleptics, frontal lobe, 40:115
neuroleptics, glucose, 40:115
neuroleptics, positron emission tomography, 40:115
neuropathology, brain stem reticular formation, 40:31
Schizophrenia continued
neuropathology, locus ceruleus, 40:31
neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
neuropathology, pedunculopontine nucleus, 40:31
neuropsychology, blood flow, 40:253
neuropsychology, Wisconsin Card Sort Test, 40:253
never-medicated patients, apomorphine, 40:135
never-medicated patients, frontal lobe, 40:135
never-medicated patients, glucose metabolism, 40:135
never-medicated patients, positron emission tomography, 40:135
never-medicated patients, temporal lobe, 40:135
nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
nicotinamide adenosine dinucleotide phosphate, post-mortem, 40:31
pedunculopontine nucleus, brain stem reticular formation, 40:31
pedunculopontine nucleus, locus ceruleus, 40:31
pedunculopontine nucleus, neuropathology, 40:31
pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
pharmacokinetics, fluphenazine, 35:107
pharmacokinetics, magnetic resonance spectroscopy, 35:107
positron emission tomography, anxiety, 40:101
positron emission tomography, apomorphine, 40:135
positron emission tomography, basal ganglia, 40:115
positron emission tomography, frontal lobe, 40:101, 40:115, 40:135
positron emission tomography, glucose metabolism, 40:11, 40:101, 40:115, 40:135
positron emission tomography, haloperidol, 40:115

Schizophrenia continued
positron emission tomography, homovanillic acid, 40:101
positron emission tomography, measurement reliability, 40:11
positron emission tomography, neuroleptics, 40:115
positron emission tomography, never-medicated patients, 40:135
positron emission tomography, prolactin, 40:101
positron emission tomography, relative vs. absolute metabolic rate, 40:11
positron emission tomography, temporal lobe, 40:135
positron emission tomography, thiothixene, 40:115
post-mortem examination, Alzheimer's disease, 35:149
post-mortem examination, astrocytosis, 35:149
post-mortem examination, dentate gyrus, 35:149
post-mortem examination, entorhinal cortex, 35:149
post-mortem examination, hippocampus, 35:149
post-mortem, nicotinamide adenosine dinucleotide phosphate, 40:31
prolactin, anxiety, 40:101
prolactin, frontal lobe, 40:101
prolactin, glucose metabolism, 40:101
prolactin, homovanillic acid, 40:101
prolactin, positron emission tomography, 40:101
relative vs. absolute metabolic rate, glucose metabolism, 40:11
relative vs. absolute metabolic rate, measurement reliability, 40:11
relative vs. absolute metabolic rate, positron emission tomography, 40:11
stability after psychosis onset, computed tomography, 40:21
stability after psychosis onset, ventricular size, 40:21
symptom severity, blood flow, 35:27
symptom severity, frontal lobe, 35:27
T2 hyperintense foci, magnetic resonance imaging, 40:239
T2 hyperintense foci, tardive dyskinesia, 40:239
tardive dyskinesia, basal ganglia, 40:157
tardive dyskinesia, magnetic resonance imaging, 40:157

Schizophrenia continued
tardive dyskinesia, magnetic resonance imaging, 40:239
tardive dyskinesia, T2 hyperintense foci, 40:239
temporal horn volume, amygdala, 35:1
temporal horn volume, hippocampus, 35:1
temporal horn volume, magnetic resonance imaging, 35:1
temporal horn volume, temporal lobe, 35:1
temporal lobe, amygdala, 35:1, 35:137
temporal lobe, apomorphine, 40:135
temporal lobe, frontal lobe, 40:135
temporal lobe, genetics, 35:137
temporal lobe, glucose metabolism, 40:135
temporal lobe, hippocampus, 35:1 35:137
temporal lobe, magnetic resonance imaging, 35:1, 35:137
temporal lobe, never-medicated patients, 40:135
temporal lobe, positron emission tomography, 40:135
temporal lobe, temporal horn volume, 35:1
temporal lobe, ventricular size, 35:137
thiothixene, positron emission tomography, 40:115
third ventricle, cranial size, 40:49
third ventricle, genetics, 40:49
third ventricle, magnetic resonance imaging, 40:49
third ventricle, ventricular size, 40:49
ventricle-brain ratio, admixture analysis, 35:61
ventricle-brain ratio, computed tomography, 35:61
ventricle-brain ratio, genetics, 35:61
ventricular size, amygdala, 35:137
ventricular size, blood-brain barrier, 40:203
ventricular size, computed tomography, 40:21
ventricular size, cortical sulcal enlargement, 40:203
ventricular size, cranial size, 40:49
ventricular size, gadolinium-DPTA, 40:203
ventricular size, genetics, 35:137
ventricular size, genetics, 40:49
ventricular size, hippocampus, 35:137
ventricular size, magnetic resonance imaging, 35:137, 40:49, 40:203
ventricular size, stability after psychosis onset, 40:21
ventricular size, temporal lobe, 35:137
ventricular size, third ventricle, 40:49

Schizophrenia continued
Wisconsin Card Sort Test, blood flow, 40:253
Wisconsin Card Sort Test, neuropsychology, 40:253
Serotonin
clomipramine, electroencephalographic topography, 40:91
clomipramine, evoked potentials, 40:91
clomipramine, fluoxetine, 40:91
clomipramine, laterality, 40:91
clomipramine, P300, 40:91
electroencephalographic topography, clomipramine, 40:91
electroencephalographic topography, evoked potentials, 40:91
electroencephalographic topography, fluoxetine, 40:91
electroencephalographic topography, laterality, 40:91
electroencephalographic topography, P300, 40:91
evoked potentials, clomipramine, 40:91
evoked potentials, electroencephalographic topography, 40:91
evoked potentials, fluoxetine, 40:91
evoked potentials, laterality, 40:91
evoked potentials, P300, 40:91
fluoxetine, clomipramine, 40:91
fluoxetine, electroencephalographic topography, 40:91
fluoxetine, evoked potentials, 40:91
fluoxetine, laterality, 40:91
fluoxetine, P300, 40:91
laterality, clomipramine, 40:91
laterality, electroencephalographic topography, 40:91
laterality, evoked potentials, 40:91
laterality, fluoxetine, 40:91
laterality, P300, 40:91
P300, clomipramine, 40:91
P300, electroencephalographic topography, 40:91
P300, evoked potentials, 40:91
P300, fluoxetine, 40:91
P300, laterality, 40:91
Sleep
affective disorder, frontal lobe, 40:247
affective disorder, hexamethylpropyleneamineoxime (HMPAO), 40:247
affective disorder, limbic system, 40:247
affective disorder, single photon emission computed tomography, 40:247
affective disorder, sleep deprivation, 40:247
Sleep continued
arecoline, electroencephalographic topography, 35:91
arecoline, polysomnography, 35:91
electroencephalographic topography, arecoline, 35:91
electroencephalographic topography, polysomnography, 35:91
frontal lobe, affective disorder, 40:247
frontal lobe, hexamethylpropyleneamine-oxime (HMPAO), 40:247
frontal lobe, limbic system, 40:247
frontal lobe, single photon emission computed tomography, 40:247
frontal lobe, sleep deprivation, 40:247
hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
hexamethylpropyleneamineoxime (HMPAO), single photon emission computed
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
tomography, 40:247
limbic system, affective disorder, 40:247
limbic system, frontal lobe, 40:247
limbic system, hexamethylpropyleneamine-oxime (HMPAO), 40:247
limbic system, single photon emission computed tomography, 40:247
limbic system, sleep deprivation, 40:247
polysomnography, arecoline, 35:91
polysomnography, electroencephalographic topography, 35:91
single photon emission computed tomography, affective disorder, 40:247
single photon emission computed tomography, frontal lobe, 40:247
single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247
single photon emission computed tomography, limbic system, 40:247
single photon emission computed tomography, sleep deprivation, 40:247
sleep deprivation, affective disorder, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, hexamethylpropylene-amineoxime (HMPAO), 40:247
sleep deprivation, limbic system, 40:247
sleep deprivation, single photon emission computed tomography, 40:247

SPECT (Single photon emission tomography)
affective disorder, frontal lobe, 40:247
affective disorder, hexamethylpropylene-amineoxime (HMPAO), 40:247
affective disorder, limbic system, 40:247
affective disorder, sleep, 40:247
affective disorder, sleep deprivation, 40:247
Alzheimer's disease, blood flow, 40:167
Alzheimer's disease, cortical circumferential analysis, 40:167
Alzheimer's disease, iodoamphetamine, 40:167
blood flow, Alzheimer's disease, 40:167
blood flow, cortical circumferential analysis, 40:167
blood flow, iodoamphetamine, 40:167
cortical circumferential analysis, Alzheimer's disease, 40:167
cortical circumferential analysis, blood flow, 40:167
cortical circumferential analysis, iodoamphetamine, 40:167
frontal lobe, affective disorder, 40:247
frontal lobe, hexamethylpropylene-amineoxime (HMPAO), 40:247
frontal lobe, limbic system, 40:247
frontal lobe, sleep deprivation, 40:247
hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
iodoamphetamine, Alzheimer's disease, 40:167
iodoamphetamine, blood flow, 40:167
iodoamphetamine, cortical circumferential analysis, 40:167
limbic system, affective disorder, 40:247
limbic system, frontal lobe, 40:247
limbic system, hexamethylpropylene-amineoxime (HMPAO), 40:247
limbic system, sleep deprivation, 40:247
sleep, affective disorder, 40:247
sleep deprivation, affective disorder, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, hexamethylpropylene-amineoxime (HMPAO), 40:247
sleep deprivation, limbic system, 40:247
sleep deprivation, sleep, 40:247
sleep, frontal lobe, 40:247

SPECT (Single photon emission tomography) continued
sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep, limbic system, 40:247
sleep, sleep deprivation, 40:247
Substance abuse
alpha power, Beck Depression Scale, 35:95
alpha power, cocaine, 35:95
alpha power, electroencephalographic topography, 35:95
Beck Depression Scale, alpha power, 35:95
Beck Depression Scale, cocaine, 35:95
Beck Depression Scale, electroencephalographic topography, 35:95
cocaine, alpha power, 35:95
cocaine, Beck Depression Scale, 35:95
cocaine, electroencephalographic topography, 35:95
electroencephalographic topography, alpha power, 35:95
electroencephalographic topography, Beck Depression Scale, 35:95
electroencephalographic topography, cocaine, 35:95
Tardive dyskinesia
basal ganglia, magnetic resonance imaging, 40:157
basal ganglia, schizophrenia, 40:157
magnetic resonance imaging, basal ganglia, 40:157
magnetic resonance imaging, schizophrenia, 40:157, 40:239
magnetic resonance imaging, T2 hyperintense foci, 40:239
schizophrenia, basal ganglia, 40:157
schizophrenia, magnetic resonance imaging, 40:157, 40:239
schizophrenia, T2 hyperintense foci, 40:239
T2 hyperintense foci, magnetic resonance imaging, 40:239
T2 hyperintense foci, schizophrenia, 40:239
Temporal lobe
amygdala, genetics, 35:137
amygdala, hippocampus, 35:1, 35:137
amygdala, magnetic resonance imaging, 35:1, 35:137
amygdala, schizophrenia, 35:1, 35:137
amygdala, temporal horn volume, 35:1
amygdala, ventricular size, 35:137
apomorphine, frontal lobe, 40:135
apomorphine, glucose metabolism, 40:135
apomorphine, never-medicated patients, 40:135

Temporal lobe continued
apomorphine, positron emission tomography, 40:135
apomorphine, schizophrenia, 40:135
frontal lobe, apomorphine, 40:135
frontal lobe, glucose metabolism, 40:135
frontal lobe, never-medicated patients, 40:135
frontal lobe, positron emission tomography, 40:135
frontal lobe, schizophrenia, 40:135
genetics, amygdala, 35:137
genetics, hippocampus, 35:137
genetics, magnetic resonance imaging, 35:137
genetics, schizophrenia, 35:137
genetics, ventricular size, 35:137
glucose metabolism, apomorphine, 40:135
glucose metabolism, frontal lobe, 40:135
glucose metabolism, never-medicated patients, 40:135
glucose metabolism, positron emission tomography, 40:135
glucose metabolism, schizophrenia, 40:135
hippocampus, amygdala, 35:1, 35:137
hippocampus, genetics, 35:137
hippocampus, magnetic resonance imaging, 35:1, 35:137
hippocampus, schizophrenia, 35:1, 35:137
hippocampus, temporal horn volume, 35:1
hippocampus, ventricular size, 35:137
magnetic resonance imaging, amygdala, 35:1, 35:137
magnetic resonance imaging, genetics, 35:137
magnetic resonance imaging, hippocampus, 35:1, 35:137
magnetic resonance imaging, schizophrenia, 35:1, 35:137
magnetic resonance imaging, temporal horn volume, 35:1
magnetic resonance imaging, ventricular size, 35:137
never-medicated patients, apomorphine, 40:135
never-medicated patients, frontal lobe, 40:135
never-medicated patients, glucose metabolism, 40:135
never-medicated patients, positron emission tomography, 40:135
never-medicated patients, schizophrenia, 40:135
positron emission tomography, apomorphine, 40:135

Temporal lobe continued
positron emission tomography, frontal lobe, 40:135
positron emission tomography, glucose metabolism, 40:135
positron emission tomography, never-medicated patients, 40:135
positron emission tomography, schizophrenia, 40:135
schizophrenia, amygdala, 35:1, 35:137
schizophrenia, apomorphine, 40:135
schizophrenia, frontal lobe, 40:135
schizophrenia, genetics, 35:137
schizophrenia, glucose metabolism, 40:135
schizophrenia, hippocampus, 35:1, 35:137
schizophrenia, magnetic resonance imaging, 35:1, 35:137
schizophrenia, never-medicated patients, 40:135
schizophrenia, positron emission tomography, 40:135
schizophrenia, temporal horn volume, 35:1
schizophrenia, ventricular size, 35:137
temporal horn volume, amygdala, 35:1
temporal horn volume, hippocampus, 35:1
temporal horn volume, magnetic resonance imaging, 35:1
temporal horn volume, schizophrenia, 35:1
ventricular size, amygdala, 35:137
ventricular size, genetics, 35:137
ventricular size, hippocampus, 35:137
ventricular size, magnetic resonance imaging, 35:137
ventricular size, schizophrenia, 35:137
Tetrahydrocannabinol
glucose metabolism, positron emission tomography, 40:69
positron emission tomography, glucose metabolism, 40:69
Thiothixene
positron emission tomography, schizophrenia, 40:115
schizophrenia, positron emission tomography, 40:115
Ventricle-brain ratio
admixture analysis, computed tomography, 35:61
admixture analysis, genetics, 35:61
admixture analysis, schizophrenia, 35:61
aging, Alzheimer's disease, 35:115
aging, cognition, 35:115
aging, computed tomography, 35:115
aging, hippocampus, 35:15
aging, limbic system, 35:15

Ventricle-brain ratio continued
aging, magnetic resonance imaging, 35:15
aging, Mini-Mental State Examination, 35:115
aging, Wechsler Adult Intelligence Scale, 35:115
alcoholism, computed tomography, 40:1
alcoholism, measurement reliability, 40:1
Alzheimer's disease, aging, 35:115
Alzheimer's disease, cognition, 35:115
Alzheimer's disease, computed tomography, 35:115
Alzheimer's disease, Mini-Mental State Examination, 35:115
Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
amygdala, genetics, 35:137
amygdala, hippocampus, 35:137
amygdala, magnetic resonance imaging, 35:137
amygdala, schizophrenia, 35:137
amygdala, temporal lobe, 35:137
blood-brain barrier, cortical sulcal enlargement, 40:203
blood-brain barrier, gadolinium-DPTA, 40:203
blood-brain barrier, magnetic resonance imaging, 40:203
blood-brain barrier, schizophrenia, 40:203
cognition, aging, 35:115
cognition, Alzheimer's disease, 35:115
cognition, computed tomography, 35:115
cognition, Mini-Mental State Examination, 35:115
cognition, Wechsler Adult Intelligence Scale, 35:115
computed tomography, admixture analysis, 35:61
computed tomography, aging, 35:115
computed tomography, alcoholism, 40:1
computed tomography, Alzheimer's disease, 35:115
computed tomography, cognition, 35:115
computed tomography, genetics, 35:61
computed tomography, measurement reliability, 40:1
computed tomography, Mini-Mental State Examination, 35:115
computed tomography, schizophrenia, 35:61, 40:21
computed tomography, stability after psychosis onset, 40:21
computed tomography, Wechsler Adult Intelligence Scale, 35:115

Ventricle-brain ratio continued
cortical sulcal enlargement, blood-brain barrier, 40:203
cortical sulcal enlargement, gadolinium-DPTA, 40:203
cortical sulcal enlargement, magnetic resonance imaging, 40:203
cortical sulcal enlargement, schizophrenia, 40:203
cranial size, genetics, 40:49
cranial size, magnetic resonance imaging, 40:49
cranial size, schizophrenia, 40:49
cranial size, third ventricle, 40:49
gadolinium-DPTA, blood-brain barrier, 40:203
gadolinium-DPTA, cortical sulcal enlargement, 40:203
gadolinium-DPTA, magnetic resonance imaging, 40:203
gadolinium-DPTA, schizophrenia, 40:203
genetics, admixture analysis, 35:61
genetics, amygdala, 35:137
genetics, computed tomography, 35:61
genetics, cranial size, 40:49
genetics, hippocampus, 35:137
genetics, magnetic resonance imaging, 35:137, 40:49
genetics, schizophrenia, 35:61, 35:137, 40:49
genetics, temporal lobe, 35:137
genetics, third ventricle, 40:49
hippocampus, aging, 35:15
hippocampus, amygdala, 35:137
hippocampus, genetics, 35:137
hippocampus, limbic system, 35:15
hippocampus, magnetic resonance imaging, 35:15, 35:137
hippocampus, schizophrenia, 35:137
hippocampus, temporal lobe, 35:137
limbic system, aging, 35:15
limbic system, hippocampus, 35:15
limbic system, magnetic resonance imaging, 35:15
magnetic resonance imaging, aging, 35:15
magnetic resonance imaging, amygdala, 35:137
magnetic resonance imaging, blood-brain barrier, 40:203
magnetic resonance imaging, cortical sulcal enlargement, 40:203
magnetic resonance imaging, cranial size, 40:49
magnetic resonance imaging, gadolinium-DPTA, 40:203

Ventricle-brain ratio continued
magnetic resonance imaging, genetics, 35:137
magnetic resonance imaging, genetics, 40:49
magnetic resonance imaging, hippocampus, 35:15,35:137
magnetic resonance imaging, limbic system, 35:15
magnetic resonance imaging, ratio measurement reliability, 40:79
magnetic resonance imaging, schizophrenia, 35:137, 40:49, 40:203
magnetic resonance imaging, temporal lobe, 35:137
magnetic resonance imaging, third ventricle, 40:49
measurement reliability, alcoholism, 40:1
measurement reliability, computed tomography, 40:1
Mini-Mental State Examination, aging, 35:115
Mini-Mental State Examination, Alzheimer's disease, 35:115
Mini-Mental State Examination, cognition, 35:115
Mini-Mental State Examination, computed tomography, 35:115
Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
ratio measurement reliability, magnetic resonance imaging, 40:79
schizophrenia, admixture analysis, 35:61
schizophrenia, amygdala, 35:137
schizophrenia, blood-brain barrier, 40:203
schizophrenia, computed tomography, 35:61,40:21
schizophrenia, cortical sulcal enlargement, 40:203
Ventricle-brain ratio continued
schizophrenia, cranial size, 40:49
schizophrenia, gadolinium-DPTA, 40:203
schizophrenia, genetics, 35:61, 35:137 40:49
schizophrenia, hippocampus, 35:137
schizophrenia, magnetic resonance imaging, 35:137, 40:49, 40:203
schizophrenia, stability after psychosis onset, 40:21
schizophrenia, temporal lobe, 35:137
schizophrenia, third ventricle, 40:49
stability after psychosis onset, computed tomography, 40:21
stability after psychosis onset, schizophrenia, 40:21
temporal lobe, amygdala, 35:137
temporal lobe, genetics, 35:137
temporal lobe, hippocampus, 35:137
temporal lobe, magnetic resonance imaging, 35:137
temporal lobe, schizophrenia, 35:137
third ventricle, cranial size, 40:49
third ventricle, genetics, 40:49
third ventricle, magnetic resonance imaging, 40:49
third ventricle, schizophrenia, 40:49
Wechsler Adult Intelligence Scale, aging, 35:115
Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115
Wechsler Adult Intelligence Scale, cognition, 35:115
Wechsler Adult Intelligence Scale, computed tomography, 35:115
Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115